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ABSTRACT

Over a billion individuals worldwide suffer from neglected diseases. This equates to
approximately one-sixth of the human population. These infections are often endemic in remote
tropical regions of impoverished populations where vectors can flourish and infected individuals
cannot be effectively treated due to a lack of hospitals, medical equipment, drugs, and trained
personnel. The few drugs that have been approved for the treatments of such illnesses are not
widely used because they are riddled with inadequate implications of cost, safety, drug
availability, administration, and resistance. Hence, there exists an eminent need for the design
and development of improved new therapeutics. Influential world-renowned scientists in the
Consortium for Parasitic Drug Development (CPDD) have preformed extensive biological
testing for compounds active against parasites that cause neglected diseases. These data were
acquired through several collaborations and found applicable to computational studies that
examine quantitative structure-activity relationships through the development of predictive

models and explore structural relationships through docking. Both of these in silico tools can
contribute to an understanding of compound structural importance for specific targets. The
compilation of manuscripts presented in this dissertation focus on three neglected diseases:
trypanosomiasis, Chagas disease, and leishmaniasis. These diseases are caused by kinetoplastid
parasites Trypanosoma brucei, Trypanosoma cruzi, and Leishmania spp., respectively.
Statistically significant predictive devices were developed for the inhibition of the: (1) T. brucei
P2 nucleoside transporter, (2) T. cruzi parasite at two temperatures, and (3) two species of
Leishmania. From these studies compound structural importance was assessed for the targeting
of each parasitic system. Since these three parasites are all from the Order Kinetoplastida and the
kinetoplast DNA has been determined a viable target, compound interactions with DNA were
explored to gain insight into binding modes of known and novel compounds.
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CHAPTER 1: NEGLECTED DISEASES

1

NEGLECTED DISEASES

Worldwide, more than a billion individuals suffer from neglected diseases; yet very few
drugs have been approved as therapeutics for these illnesses.1-3 The lack of therapeutic agents
and the adverse effects of those available necessitates drug discovery efforts. Studies addressed
in this compilation of manuscripts are for neglected diseases caused by parasites of the Order
Kinetoplastida: (1) trypanosomiasis, caused by Trypanosoma brucei, (2) Chagas disease, caused
by Trypanosoma cruzi, and (3) leishmaniasis, caused by species of Leishmania.

Therapeutics

Trypanosomiasis. The type of treatment for trypanosomiasis depends on the stage of
infection, first or second, and subspecies of parasite.4-7 Suramin is used to treat T. brucei
rhodesiense infections, while pentamidine is employed for T. brucei gambiense. Side effects of
suramin treatment include nausea, vomiting, urticarial rash and lack of consciousness, whereas
pentamidine’s side effects include hypotension, abdominal pain, hypersalivation, vertigo, nausea,
and chest pain. The second stage treatments for both subspecies calls for melarsoprol, a drug that
is highly toxic and consists of the following side effects: convulsions, fever, loss of
consciousness, rashes, bloody stool, nausea, and vomiting, as well as myocardial damage,
albuminuria, and hypertension. Eflornithine can also be employed to specifically treat T. brucei
gambiense. The side effects associated with this compound include diarrhea, suppression of bone
marrow, anaemia, and leukopenia.
2

Chagas Disease. Accepted clinical treatments for Chagas disease are Nifurtimox (Nfx)
and Benznidazole (Bz); these compounds are not FDA approved.7-9 The most common side
effects of Nfx are abdominal pain, dizziness, headache, loss of appetite, nausea, vomiting, and
weight loss, whereas the most common side effects of Bz include gastrointestinal symptoms such
as nausea and peripheral neuropathy.

Leishmaniasis. Infections of Leishmania spp. result in three forms of the leishmaniasis
disease: cutaneous, mucosal, and visceral.3,

4, 7, 10, 11

The preferred treatments are sodium

stibogluconate for cutaneous and mucosal leishmaniasis and liposomal amphotericin B for
visceral leishmaniasis. However, due primarily to the high cost of liposomal amphotericin B,
sodium stibogluconate is commonly used to treat all three leishmaniasis disease forms. The most
common side effect of sodium stibogluconate includes thrombophlebitis, abdominal pain,
nausea, vomiting, anorexia, myalgia, arthralgia, and headache. The most predominant side effect
of amphotericin B is nephrotoxicity.

Research Approach

Biological testing data were acquired through collaborations with world-renowned
scientists in the Consortium for Parasitic Drug Development (CPDD). The compounds and their
respective activities were employed for computational studies that examine: (1) quantitative
structure-activity relationships (QSAR) through the development of predictive models and (2)
explore structural relationships through docking.
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Predictive Models. The QSAR of the structural and biological data acquired was assessed
through partial least squares (PLS) regression modeling employing the biologically obtained
activities and computationally calculated comparative molecular field analysis (CoMFA) and
comparative molecular similarity indices analysis (CoMSIA) molecular descriptors. In general,
QSAR-PLS studies follow these steps of progression: (1) compound input, (2) compound
minimization, (3) compound alignment, (4) molecular descriptor calculation, and (5) regression
model formation.

Before QSAR-PLS predictive models can be formed, an extensive dataset of compound
structures with biological activities must be acquired; it is important that biological activities are
gained by the same biological assay for each compound of the dataset. Compounds employed for
QSAR-PLS predictive modeling can consist of several diverse backbones. More diversity in a
molecular modeling system leads to a greater range of structures applicable for prediction.

When employing the SYBYL12 software environment to a dataset of compounds with
biological activities, the Sketch Molecule menu can be opened and compounds may be drawn.
Upon completion of a compound the Sketch Molecule menu needs to be exited and the
compound ought to be named via the Name Molecule menu. The molecules should then undergo
an initial minimization which can be done using the Minimize Molecule option. Examples of
constructed and minimized structures may be viewed in Figure 1. Each named structure can then
be placed into a constructed database through the Database Put Molecule option.

4

Subsequently to the input of all compounds into the database, possible conformations of
structures should be assessed. This can be done through several methods including but not
limited to: Systematic Conformational Search, Grid Search, Random Conformational Search,
MultiSearch, and GA Conformational Search. The lowest energy conformations of compounds
obtained ought to be further studied. To insure that compounds are in their lowest energy
conformations these compounds may be re-minimized and moved to new databases. Figure 2
displays three low energy structures of an arylimidamide compound.

Compounds of similar low energy structural conformations ought to then be aligned; each
alignment should consist of only one structural representation for each compound of the dataset.
Alignment can be acquired in several ways including but not limited to: Fit Atoms, Match
Atoms, Superimpose Atoms, Multifit, GALAHAD, and GASP. Examples are displayed in Figure
3. Optimal compound alignment is essential to the construction of employable QSAR-PLS
models.13

A molecular spreadsheet ought to be constructed following alignment; this can be done
by opening the database through the Open menu. Biological activities can then be input into the
spreadsheet and molecular descriptors may be calculated by using the AutoFill menu of the
spreadsheet. CoMFA and CoMSIA molecular descriptors can be calculated for QSAR-PLS
modeling.14 CoMFA has become a model system for QSAR modeling methods and CoMSIA
was developed to overcome limitations of CoMFA.14,

15

For CoMFA, each compound of a

dataset is assigned interaction energies with respect to a probe atom and steric and electrostatic
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molecular descriptors are calculated with a particular potential function; Lennard-Jones and
Coulomb potentials, respectively.16 To keep the calculation energies in reasonable boundaries
cut-off values are fixed: 5 kcal/mol for the Lennard-Jones potential and ±30 kcal/mol for the
Coulomb potential. For CoMSIA, similarity indices are compiled for the compounds of a dataset
at the intersections of a regularly spaced lattice.13, 16, 17 This is conducted with a grid and probe
method, similar to CoMFA. In CoMSIA, a common probe is employed in a distance dependent
approach that scans the entirety of the lattice and embeds each compound; the lattice points
inside and outside the molecule are employed and cut-offs are not needed. Steric, electrostatic,
hydrophobic, donor, and acceptor molecular descriptors are calculated using positive and
negative fields acquired through similarity indices. The CoMSIA method indirectly evaluates the
similarities of each molecule in the dataset, whereas the CoMFA method evaluates the
compounds of the dataset through relative interaction energies dependant on molecular positions.

PLS can then be employed to compare the biological activities of compounds to their
respective calculated molecular descriptors; the PLS regression technique solves the linear model
in a stepwise approach that includes every predictor variable in the model.12 A separate QSAR
equation is prepared for each target property when multiple dependent variables are employed.
The resulting coefficients are interrelated and usually differ from those that would be obtained by
examining biological properties individually. An illustration of this regression technique can be
viewed in Figure 4. With high-quality biological data and compound alignments as described
above, predictive QSAR-PLS models can be acquired.

6

Docking. When receptor structures are available, useful information can be obtained
through the docking of compounds into a binding site. Figure 5 displays the general scheme of
FlexiDock, a genetic algorithm-based flexible docking method. Geometry optimization produces
an initial population of compounds in complex with a receptor. Each complex consists of
parameters that will be optimized: torsional angles, translation, and rotational angles.
Reproduction takes place when complex populations swap coordinates, crossover, and/or exhibit
random changes within the complex, mutation. Duplicate checking ensures that each complex is
unique; this increases the complex population diversity. Conformational modifications are then
made to the reproduced compounds and an evaluation function for scoring the resulting
interaction is applied to the complex. The FlexiDock scoring function is based on the Tripos
force field and estimates the energy of the compound, the receptor, and the complex energy. The
score is evaluated with van der Waals and the user-selected energy terms, including electrostatic,
torsional, constraint, and hydrogen bonding energies; lower energy in the complex state suggests
better binding. The crossover options that can be implemented when using Flexidock include:
(1) successive generations, (2) the creation of new members, created via crossover and mutation,
and (3) parents that can be selected for crossover. Fitness scores can be scaled to aid in selection.

Manuscripts

The published and unpublished manuscripts presented in this dissertation are a result of a
series of studies examining neglected diseases through the employment of biological data and
computational tools to examine respective parasites and relevant druggable targets.18-21 Chapters

7

two through five represent four independent studies. Chapter two examines a highly diverse
dataset of inhibitors for T. brucei P2 transporters. A QSAR-PLS model was acquired through this
study and the compounds of the model were examined to gain an understanding of inhibitory
compound structural importance for P2 transporter inhibition. Chapter three examines
arylimidamides and their inhibitory activity against two species of Leishmania. This research
endeavor resulted in a conservative predictive method acquired via predictive models employing
both rigid and flexible compound alignments. Compound structural importance to activity was
then assessed. Chapter four examines a dataset of diamidines and arylimidamides with respect to
inhibitory activity against T. cruzi at two different temperatures. A pharmacophore was obtained
and used to construct a predictive model. Inhibitory compound importance was then extrapolated
from the model and assessed with respect to the pharmacophore at each temperature. Chapter
five examines dimer polyamide compounds bound by DNA with respect to their cognate DNA
sequences. Structural importance and mechanisms of binding were evaluated through docking
analyses. This study provides insight into DNA-compound interactions that may be applicable
for targeting parasites of the Order Kinetoplastida, since the DNA of these parasites has been
identified as druggable targets.22-24
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1. Compounds were input into SYBYL 8.1.

Scaffold Structure 1.
Backbone of 46
Figures
training and all 12
testing compounds.

Scaffold Structure 2.
Backbone of DB1881,
DB1882 and 1910.

Scaffold Structure 3.
Backbone of DB1911
and DB1945.

Figure 1. Examples of compounds constructed and minimized within the molecular modeling
software. Minimization should include an assigned Force Field, such as Tripos, and Charges,
such as Gasteiger-Huckel.
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Minimized Conformation
2. Subsequent to a short molecular dynamics simulation of 1ns, each low
energy compound was minimized to convergence employing the Tripos force
field and Gaseiger-Huckel charges.

Figure 2. Possible conformations of structures can be explored through various methods.

13

3. Three-dimensional molecular structures were overlaid in Cartesian space.
(A) The QSAR module was employed to overlay rigid low energy structures
via individual molecule translations and/or rotations. (B) The GALAHAD
module was used to overlay flexible molecular structures in torsional space.
Resulting rigid conformations were then overlaid within the Cartesian space.

(A)

(B)

Figure 3. The three-dimensional molecular structures aligned within Cartesian space. (A) The
QSAR module of SYBYL can be employed to overlay rigid low energy structures via individual
molecule translations and/or rotations. (B) The GALAHAD module of SYBYL can be used to
overlay flexible or rigid molecular structures in torsional space. The identified features are color
coded: cyan for hydrophobes, magenta for donor atoms, green for acceptor atoms and red for
positive nitrogens.
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east Squares (PLS)

used
values
ptors;

Molecular Descriptor 3
t2
t1
Molecular Descriptor 1
Molecular Descriptor 2
Figure 4. Partial least squares (PLS) is a regression technique that is employed to compare
experimentally obtained activity values to compound molecular descriptors acquired from
respective compounds. PLS results in a linear model.
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Figure 5. FlexiDock employs genetic algorithms as global optimizers to apply methods of
biological evolution.
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CHAPTER 2: PREDICTIVE COMPUTATIONAL MODELS OF SUBSTRATE BINDING
BY A NUCLEOSIDE TRANSPORTER
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Transporters play a vital role in both the resistance mechanisms of existing drugs and
effective targeting of their replacements. Melarsoprol and diamidine compounds similar to
pentamidine and furamidine are primarily taken up by trypanosomes of the genus Trypanosoma
brucei through the P2 aminopurine transporter. In standardized competition experiments with
[3H]adenosine, P2 transporter inhibition constants (Ki) have been determined for a diverse
dataset of adenosine analogs, diamidines, Food and Drug Administration-approved compounds
and analogs thereof, and custom-designed trypanocidal compounds. Computational biology has
been employed to investigate compound structure diversity in relation to P2 transporter
interaction. These explorations have led to models for inhibition predictions of known and novel
compounds to obtain information about the molecular basis for P2 transporter inhibition. A
common pharmacophore for P2 transporter inhibition has been identified along with other key
structural charisteristics. Our model provides insight into P2 transporter interactions with known
compounds and contributes to strategies for the design of novel antiparasitic compounds. This
approach offers a quantitative and predictive tool for molecular recognition by specific
transporters without the need for structural or even primary sequence information of the transport
protein.
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Introduction

Trypanosoma brucei are unicellular trypanosomal parasites that cause African sleeping
sickness in humans and nagana in livestock. These trypanosomes are auxotrophic for purines and
thus rely entirely on purine supplies salvaged from the host environment. As such, T. brucei
brucei expresses a multitude of purine nucleoside and nucleobase transporters.1 One of these, the
T. brucei aminopurine P2 transporter, is unusual as a genuine nucleoside-nucleobase transporter
in that it equally transports the nucleoside adenosine and the nucleobase adenine but has virtually
no affinity for any other natural purines or pyrimidines.1-3 Yet, despite this apparent high level of
selectivity, it has been shown that P2 also mediates cellular uptake of the Food and Drug
Administration-approved drugs melarsoprol and pentamidine,2,

4,

5

the main veterinary

trypanocides diminazene aceturate6 and possibly isometamidium,7 and various nucleoside drugs.8

The unusual nature of this transporter has led to efforts to exploit it as an efficient conduit
for novel trypanocides,9, 10 but this requires the identification of the exact pharmacophore as well
as the physical limitations on size and charge distribution of the extracellular binding site of the
transporter. From the structural similarities between known P2 substrates, it could be concluded
early on that the so-called amidine motif of adenine, i.e. N(1)=C(6)−NH2 (see Figure 1), was
very likely to play a major role in the high affinity interaction with the transporter.3, 11 However,
quantitative information or three-dimensional models explaining the high affinity binding, by
one transporter, of such diverse molecules as adenosine (Figure 1A),2,

20

3

stilbamidine (Figure

1C),12 melarsoprol (Figure 1F),2,

3

and even isometamidium (Figure 1G),7 have not been

available. The apparent broad selectivity has been all the more intriguing for the highly similar
transport efficiencies of P2 for adenosine and adenine, a most unusual feature for nucleoside
transporters.1

To construct a predictive and quantitative model of P2-substrate interactions, we
determined the Ki values of a large number of highly diverse potential inhibitors, with affinities
ranging over several orders of magnitude, through competition experiments with radiolabeled
adenosine. These values and structures were then employed for a computational modeling
approach to gain more information about the molecular basis for P2 transporter inhibition. The
resulting model can be used to evaluate the affinity of the P2 transporter for existing and novel
compounds in silico, potentially aiding in the development of novel and selectively targeted
trypanocides. More important yet, this strategy allows robust three-dimensional insights into
transporter-ligand binding while not requiring knowledge of the structure, or indeed the
sequence, of a transporter and can be applied to any solute transport mechanism for which uptake
or binding experiments can be routinely performed.

Experimental Procedures

Transport of [3H]Adenosine by Bloodstream Forms of T. brucei. Bloodstream forms of T.
brucei brucei strain 427 were taken from stocks in liquid nitrogen and injected in adult female
Wistar rats, from which they were harvested by exsanguination by cardiac puncture at peak
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parasitaemia. Parasites were isolated from the blood by elution over a DE52 column
(Whatman)13 and washed twice in assay buffer (AB: 33 mM HEPES, 98 mM NaCl, 4.6 mM
KCl, 0.3 mM CaCl2, 0.07 mM MgSO4, 5.8 mM NaH2PO4, and 14 mM glucose, pH 7.3). Cells
were resuspended in this buffer at approximately 108 cells/ml prior to use in transport
experiments. Cell counts were performed using a haemocytometer. Transport of [ 3H]adenosine
(20-40 Ci/mmol; Amersham Biosciences) was performed exactly as described previously,14 in
the presence of 250 M inosine to block the P1 adenosine uptake system. Briefly, 100 l of 50
nM [3H]adenosine, mixed with various concentrations of nonradiolabeled test compounds, was
added to 100 l AB containing 107 trypanosomes and incubated at room temperature for 30 s,
within the linear phase of uptake.3 Uptake was terminated by the addition of 1 ml of ice-cold
assay buffer containing 1 mM adenosine followed by immediate centrifugation through an oil
layer to separate cells from external radiolabel. The amount of radiolabeled adenosine inside the
cell was then determined using a scintillation counter and corrected for externally associated
label as described previously.14 A plot of inhibitor concentration versus adenosine uptake rate
(expressed as pmol(107 cells-1s-1)) yielded sigmoidal curves with Hill coefficients of
approximately −1, consistent with monophasic competitive inhibition (Prism 4.0; GraphPad).
Inhibition constants were calculated from the EC50 values, using the Cheng-Prusoff equation as
described previously.12

Inhibitor Dataset. Compounds were acquired from several academic laboratories as well
as purchased from various commercial sources. Their respective in vitro transport activities
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along with the compound names and sources are shown in Supplemental Table 1 (Appendix A).
Employing the formula pKi = −log(Ki), the Ki µM values for the 112 compounds were converted
to corresponding pKi values. The pKi values for this training set span more than 4 log units.

Software. All 112 compounds were constructed in silico with the SYBYL 8.115 software
package on a Fedora Core 5 Linux workstation. Compound structures were minimized to
convergence using a conjugate gradient of 0.01 kcal/(mol Å) and a maximum of 104 iterations
employing the Tripos force field with Gasteiger-Hückel charges. A three-dimensional cubic
lattice with 2 Å grid spacing in all directions was created to analyze compounds that were
aligned as described below. No improvement was seen in the models when the grid spacing was
reduced to 1 Å.16

Initial Alignment. Through the implementation of the SYBYL software alignment
modules, the compounds were three-dimensionally arranged by an initial analysis of structurally
and chemically related atoms. Algorithm generated alignment was performed using the align
database command, whereas the atom-to-atom alignment implemented the match feature of the
alignment tools. The algorithm alignment took place first by employing similar backbone
structures so that the majority of similar compounds were overlaid in the same molecular space.
Structurally related compounds were then moved into separate databases. The compounds that
belonged to the same structural classes, but which varied in atom types or had slight structural
differences, were placed into respective databases and aligned to the most structurally related
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compound using atom-to-atom alignment. Seven optimum databases of compounds resulted
from initial alignment.

When more rigid compound structures, consisting of a larger number of atoms, were
selected as scaffolds for alignments a greater number of databases were created. These databases
lacked the variation necessary to form Comparative Molecular Field Analysis (CoMFA) and
Comparative Molecular Similarity Indices Analysis (CoMSIA) models for predictability. Also,
when the databases were aligned by less rigid scaffolds, consisting of a smaller number of atoms,
fewer models resulted, and the models produced were not statistically significant in terms of q2cv.
The best models were obtained when compounds were aligned by the carbons of common
compound backbones. These scaffolds for alignment were obtained from the compounds
displayed in Figure 1: dataset A, adenine; dataset B, furamidine; dataset C, stilbamidine; dataset
D, pentamidine; dataset E, 1,1’-(nonane-1,9-diyl)diguanidine; dataset F, melarsoprol; and dataset
G, isometamidium. Datasets E-G are comprised of four, seven and four compounds, respectively.
The alignment for these last three datasets can be viewed in Supplemental Figure 1 (Appendix
A). These databases together consist of less than 8% of the total compounds. Because the
purpose of the initial alignment was to determine the pharmacophore for the final alignment,
only initial datasets A-D were evaluated through statistics and contour maps. All 112 compounds
were included in the final pharmacophore models.

Multiple Regression Analysis. CoMFA and CoMSIA Quantitative Structure-Activity
Relationship (QSAR) models were generated for molecular databases through a Partial Least
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Squares (PLS) multiple regression analysis with molecular descriptors as independent variables
and the pKi values as dependent variables. Statistical significance in the form of q2cv was
assessed through the leave-one-out cross-validation method. The number of components (n) was
determined by the smallest predicted error sum of squares, a value that does not always
correspond to the highest correlation coefficient (q2) value. Further statistical significance
assessment was preformed for the final model using 10-fold cross-validation. The values
obtained from the 10-fold cross-validation assessment are averages of ten trials implementing
random compound selection. Column filtering did not improve the signal to noise ratio.15

Molecular Descriptors. There are two CoMFA molecular descriptors. The steric van der
Waals interaction and the electrostatic Coulombic interaction descriptors were calculated at each
lattice intersection using a probe, an sp3 carbon atom with a formal +1 charge. Standard scaling
and default energy cutoffs were employed. There are five CoMSIA molecular descriptors. Steric,
electrostatic, hydrophobic, hydrogen bond donor and hydrogen bond acceptor descriptors were
calculated using a standard probe: 1 Å radius, +1 charge, +1 hydrophobicity, +1 hydrogen bond
donor, and +1 hydrogen bond acceptor. Steric descriptors are related to the third power of the
atomic radii. Electrostatic descriptors are derived from partial atomic charges. Hydrophobic
descriptors are derived from atom-based parameters. Hydrogen bond donor and acceptor atoms
are derived from experimental values.

Three-Dimensional Contour Analysis. The interactions of CoMFA and CoMSIA
descriptors were visualized through the mapping of the product standard deviation with respect
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to molecular descriptor values and coefficients (StDev*Coeff) at each lattice point. For the initial
models, the default levels of contour by contribution were employed as follows: 80% for a
favored region and 20% for a disfavored region. Data were analyzed, and a common
pharmacophore was identified. The compounds of the final pharmacophore model were further
analyzed through a contour by actual analysis, where the software output assisted in the
determination of proper ranges for assigned values of favored and disfavored contour regions.

Pharmacophore Model. Common contours for the initial QSAR models were identified
through the analysis of favored and disfavored contour regions. The alignment of such contours
aided in the identification of a final pharmacophore. All compounds were realigned, and the final
models were constructed.

Results

As seen in Supplemental Table 1 (Appendix A), this study employs 112 compounds
acquired from several academic and industry locations. These compounds all exhibit some level
of inhibitory activity for the T .brucei brucei P2 transporter. For large datasets of compounds
with known activity values, it is possible to employ computational biology to investigate the
molecular basis of their activity in terms of structural contributions to Ki values. Predictive
models can then be constructed, and important interactions can be identified. Because a large
number of diverse compounds are in our database, a two-step procedure was used to establish a
final model.
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Initial QSAR Models. As a first step, compounds were obtained in their minimal energy
conformation by using standard molecular mechanics energy minimization methods with the
Tripos force field. Compound alignment by similar atoms of backbone structures initially
separated the 112 compounds into seven databases, although the majority of the compounds
resided in four of the sets. The datasets with the majority of compounds were used for initial PLS
modeling. Table 1 displays the total number of compounds in each dataset, the n used in PLS,
and the statistics for each model as follows: cross-validated q2 (q2cv), the standard error of
estimate (SEE), the coefficient of determination (r2) and the F statistic. When q2 is greater than
0.5, a model is said to have predictability better than chance; however, it is also important that
the r2 value is near one, the SEE is small, and the F statistic is large.15 The r2 is a positive value
between zero and one; with one being the best correlation and zero being no correlation. The
SEE is a measure of the accuracy of the predictions. The F statistic is used in comparing the
variance between the experimental and predicted values; a larger value indicates a more
statistically significant model.

The average statistics for the initial four models with CoMFA molecular descriptors are
as follows: q2cv equal to 0.64; SEE equal to 0.23; r2 equal to 0.95; and F statistic equal to 123.
Similarly, the average statistics for the four models with CoMSIA molecular descriptors were as
follows: q2cv equal to 0.58; SEE equal to 0.26; r2 equal to 0.92; and F statistic equal to 130.
Although the models with CoMFA and CoMSIA molecular descriptors were comparable, the
ones with CoMFA molecular descriptors display better overall potential for analysis of molecular
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descriptor contribution by contour maps. This is primarily due to the simplicity of two versus
five molecular descriptors.

Contour maps of CoMFA molecular descriptor contribution were generated for each
model (Figure 2). The electrostatic interactions are shown as red and blue contours, and the steric
interactions are displayed as green and yellow contours. Increasing partial positive charge is
favored in blue regions, and increasing partial negative charge is favored in red regions, whereas
increasing bulk in substituents is favored in green regions and disfavored in yellow regions.

The red, blue, yellow, and green regions were then analyzed to find common alignment
features of structures that are of importance for the final, combined pharmacophore alignment.
Red regions of dataset A are in the areas above C6, below N9, and beside the imidazole ring of
adenine, while those of datasets B-D were localized to a single location most often than not on
the backbone structure. The red contours of datasets A-D can be aligned in several ways to one
another; thus, this descriptor alone is not enough to find the final pharmacophore for alignment.
The blue regions were most commonly found in areas of N(R1)=C(R2)−NH(R3), where R3 is
usually H. The alignment was much improved with the inclusion of both the red and blue regions
and further enhanced by the addition of the yellow and green regions. Yellow contour regions
can be reduced by realignment of compounds into green regions. The yellow regions for dataset
A are small in relation to all other contours, and reside near the 2’- and 3’- hydroxy groups of the
ribose moiety. Dataset B exhibited yellow contours on both ends of the furamidine backbone,
whereas dataset C displayed a yellow contour only at one end of the stilbamidine backbone. The
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areas of yellow contour appear most at regions that consist of several compounds with
substituents that are not precisely aligned, either because they differ largely in structure or
because the backbone allows for deviations in the alignment. Dataset D consisted of yellow
regions in the areas consisting of compounds that were longer than pentamidine and/or that did
not align fully to the pentamidine backbone. Green regions of dataset A were shown above C6
and next to bond C8/N9 of the adenine backbone, whereas the green contours of dataset B appear
near and encompassing the phenyl with the most precise alignment. Datasets C consists of green
contour near the most precise alignment of the compounds. For dataset D, green contours were
located in areas that were not precisely aligned to the pentamidine structure. The green and
yellow contours of dataset D both reside in areas of structural deviation; however, the green
appears nearest the aromatic linking oxygen and the unaligned amidines.

The identification of important structural features, described above, made it possible to
realign all 112 compounds, primarily by the common N(R1)=C(R2)−NH(R3) structure found in
the blue contour regions and secondarily by the other contour regions. The red regions of the
four main datasets overlapped strongly, whereas the yellow regions of datasets B-D can be
aligned to green regions of dataset A. The large compounds of dataset A also had to be realigned.
Figure 3A displays the alignment of all 112 compounds with adenine displayed in purple and
Figure 3B zooms in on the location of the adenine now with the purple displayed as transparent,
and this clearly shows the pharmacophore alignment.
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Final Pharmacophore Model. Aligned by the N(R1)=C(R2)−NH(R3) structure with
respect to contour regions, as described above, compounds were then employed for PLS
modeling. As before, CoMFA and CoMSIA models were generated and examined for statistical
significance. The two models each consisted of 112 compounds but use different molecular
descriptors and a different n. Although the q2cv values are similar, the remaining statistics are not;
the model with CoMFA molecular descriptors achieved a higher level of confidence than the
model with CoMSIA molecular descriptors (Table 2). To further validate these models, 10-fold
cross-validation was performed. The q210-Fold values for the models with CoMFA and CoMSIA
molecular descriptors were 0.56 and 0.54, respectively. These values, along with the rest of the
statistics, indicate statistical significance within each model.

The calculated predictions of the models formed from the dataset with 112 compounds
exhibit linear relationships with the experimental Ki values (Figure 4). Predictions from the
model with CoMSIA molecular descriptors are somewhat scattered, especially at high affinity,
whereas the model with CoMFA molecular descriptors produces more linear pKi predictions,
especially for compounds with high affinity for the P2 adenosine transporter (Figure 4). The r2
values for the linear relationships are 0.95 for the model with CoMFA molecular descriptors and
0.86 for the model with CoMSIA molecular descriptors.

These models can be further evaluated through examination of the final contour maps.
Although it is useful to analyze models as a whole to gain information about a possible
pharmacophore, once a pharmacophore model is obtained, much more information can be
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gathered by evaluating the contour regions of individual compounds within the model. Because
the model with CoMFA molecular descriptors is outperforming the model with CoMSIA
molecular descriptors, the focus of this analysis will remain on the contours of the model with
CoMFA molecular descriptors. As before, the steric contributions are displayed in yellow and
green while the electrostatic contributions are shown in red and blue.

The overall contour regions from the initial model have changed significantly with
realignment and incorporation of all 112 compounds. These changes appear most dramatic when
looking at individual compounds. In the initial models, each compound contributed roughly 2.86.3 percent. This was due to similar compounds being aligned by a common backbone scaffold
and their being only 16-36 compounds in each dataset; 1 in 36 is approximately 2.8 percent and 1
in 16 is about 6.3 percent. This percent of contribution is much larger than the final model, where
1 in 112 compounds is roughly 0.89 percent. It is also important to note that a larger quantity of
compounds with similar backbones will have a significant effect on the contribution. Hence,
based on initial models, the compounds with the adenosine scaffold structure should contribute
the most. There are 36 of these compounds. Those with the pentamidine and stilbamidine
scaffolds are similar and align to one another well within the final model. There are 32 of these
compounds, whereas there are 29 compounds related to furamidine.

From close observations of compound structure relationships in the form of contour
maps, it is possible to determine where partial charge addition or subtraction to substituents
could improve compound interactions with the P2 adenosine transporter. The evolutionary
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process by which this model calculates predictions can be viewed through the evaluation of
contour regions and experimentally determined Ki values (Figure 5). The Ki of 2-aminopyridine
is 14 µM. When an amino group is added into the favorable steric and positive electrostatic
contour regions to form 4,6-diaminopyrimidine the Ki becomes 3.2 µM. Note that the amino
group has a partial positive charge. This amino group addition thus results in improved affinity.
When the additional groups, which reside in even more favorable contour regions, are added to
the compound structure, the Ki value becomes even smaller. Adenine is an example of a
compound with groups residing in favorable contour regions. This compound has a Ki of 0.30
µM. When a compound interacts with both positive and negative contour regions, the Ki
increases; the Ki value for adenosine, for example, increases three-fold relative to adenine as a
result of the bulky ribose group. The evolutional process taken when using these potentials to
design compounds for synthesis is quite similar to the progression shown in Figure 5. It is
important to make small changes and evaluate how the designed compound will fit within the
steric and electrostatic potentials assigned by the model.

Other important compounds to evaluate with this model are the pentamidine-,
furamidine-, and melarsoprol-like compounds (Figure 6). Pentamidine, furamidine, and
melarsoprol all have good affinity for the P2 transporter with respective Ki values of 0.37, 1.19
and 0.54 µM. Contour regions of pentamidine, furamidine, and melarsoprol are displayed in
Figure 6. These regions display several areas where some steric bulk and partial positive charge
can be added to improve affinity for the P2 adenosine transporter. A loss of affinity will occur if
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bulky substituents interact with the unfavorable yellow contour regions and/or if positive charge
interacts with the red contour regions.

With pentamidine, which is a very flexible compound, the final pharmacophore model
yellow contours display most central atoms to be suitable for substituent addition; however, the
area nearest the pharmacophore should not be modified. Melarsoprol is a more rigid structure,
though rotation can occur throughout the compound. There can be rotation between the
melamine ring and the phenyl and between the phenyl and the dithiarsolan ring. For this
compound, the yellow contours reside near the melamine and the phenyl. This suggests that a
loss of affinity may result from substituent addition to the atoms in these regions. Furamidine is a
much more rigid and curved structure. For this structure, the yellow contours are much more
abundant near the phenyls and yet away from the furan and the amidines. This is even clearer
when the compound and its contour are viewed in three-dimensional space. The areas where
yellow contours do not exist are optimum for substituent modification.

The red contours encompass both pentamidine and furamidine, whereas blue contours
surround melarsoprol. The blue contours appear to be based on the partial charge distribution.
For the diamidine compounds the partial charge distribution is strongly localized at the amidines.
This appears beneficial for binding to the transporter; however, it is evident that more charge to
an amidine location will not improve binding. Instead a partial charge distribution that is shared
within a ring structure appears to be more advantageous. This is seen in the melamine-like
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structure of melarsoprol. Findings suggest that additional charge, which is less localized, may be
able to improve binding of diamidine compounds.

Discussion

The efficacy of many drugs is determined to a large extent by the processes that govern
their uptake into the cell or into the cellular compartment that is the site of action.7, 17-19 These
processes obviously include transporters for water-soluble drugs but even rates of diffusion for
lipophilic drugs. An example of the latter is chloroquin, which as a weak base diffuses across
several membranes before it reaches the Plasmodium falciparum food vacuole where it is
trapped by protonation and fatally inhibits heme polymerization.20,
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Equally, efflux systems

such as ATP-binding cassette transporters and the P. falciparum CRT1 channel-like protein have
been implicated in resistance to drugs ranging from antibiotics and antiparasitics to
antineoplastic drugs.22, 23 As such, detailed insights into the processes that determine drug flux
across the (plasma) membranes of target cells are vital for the rational optimization of drug
activity and both the prevention and bypassing of drug resistance.

It is of pivotal importance that we gain insight into the molecular mechanisms by which
transporters bind and thus select their substrates as this would allow us to construct models with
predictive value, which would allow us to optimize substrate design. Although in silico screening
of virtual libraries and predictions of substrate affinity are now possible for proteins with known
or computable structure,24-26 this is not ordinarily possible for transporters as very few structures
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have been obtained, and the protein structures, with usually 10–12 transmembrane domains, are
highly complex and extremely difficult to crystallize, although there have recently been some
notable successes, mostly with prokaryotic membrane proteins.27-29 One approach is to use the
few known transporter structures as scaffolds for other transporters, by a computational process
called fold recognition or threading. We recently obtained a model for the T. brucei brucei
nucleobase transporter NBT1 by this process and validated it by site-directed and random
mutagenesis.30 The creation of a structural model of the closely related Leishmania donovani
LdNT1.1 nucleoside transporter by ab initio calculation was also very recently reported.31
Although these approaches did produce approximate models for the overall structure of the
transporters and identified key amino acid residues, they allow at best limited prediction of
substrate selection, and only if the amino acids involved in binding have been separately
identified. Thus, with the current technologies, it is exceedingly difficult to obtain the required
functional insights with the protein structure as a starting point.

A radically different approach was pioneered some time ago to study purine transport in
T. brucei brucei by systematically altering the substrate and calculating inhibition constants, Ki,
and from there binding energy G0.1, 18 This method was used to explain substrate preferences of
purine and pyrimidine transporters in T. brucei brucei,32 Leishmania major,33,
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Toxoplasma

gondii,35 Leishmania mexicana,36 as well as the human NBT1 nucleobase transporter,14 human
concentrative nucleoside transporters,37 and human equilibrative nucleoside transporters38 with
semi-quantitative models of substrate binding that did not require any structural or genetic
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information about the transport protein. However, this method still did not allow genuinely
quantitative or three-dimensional predictions nor was it suitable for screening virtual libraries.

In this study, we have adapted the method to address the above issues; energy-minimized
three-dimensional structures of 112 compounds with experimentally obtained binding affinities
for the TbAT1/P2 transporter were employed through the use of CoMFA and CoMSIA
molecular descriptors for PLS model regression construction and analysis. The various
molecules were preliminarily aligned by their common structural and chemical features, resulting
in four datasets of compounds, Figure 2, A-D, large enough for individual model formation and
analysis. This was followed by optimized alignment of all 112 compounds using four molecular
descriptor contour potentials, negative and positive steric and electrostatic, as a guide. This has
generated an in silico computational model into which new molecules can be entered to arrive at
a reliable estimate of binding energy. This constitutes a first computational approach to the
design of novel ligands for the TbAT1/P2 transporter and allows for in silico evaluation of large
numbers of known and novel compounds as substrates. The computational analysis was
validated to be statistically significant using leave-one-out cross-validation and 10-fold crossvalidation, as well as by other statistics and the internal predictability of this model, as displayed
in Figure 4.

The contour profiles of steric and electrostatic factors also allow fundamental insights
into how various ligands interact with the transporter binding pocket. The P2 transporter, with its
highly unusual substrate profile and involvement in drug transport and resistance,2-5, 11, 39 was
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chosen for this study to gain insight into how a transporter that is on the one hand completely
selective for adenine and adenosine only (out of all nucleosides and nucleobases) can also bind
molecules as diverse as isometamidium, melarsoprol, and furamidine with similar affinity.
Previous studies already identified the “amidine” motif formed by R1−N1=C6(R2)−NH2 of
adenine as the main motif responsible for P2 binding,3,

11

and it was further argued that the

positive charge on N9 of adenine and adenosine, as well as the aromaticity of the purine, also
makes important contributions to the high substrate affinity.3, 18

The calculated substrate-transporter interaction contours for adenine and adenosine in
Figure 5 now allow us to evaluate these earlier conclusions against the advanced modeling
approach employed in this study. Figure 5 identifies four substrates that have a partial positive
charge on the position of the amino group of 2-aminopyridine/adenine/adenosine as essential for
optimal binding. Similarly, a partial negative charge is strongly favored at position 1, along with
a positive charge at positions 8 and 9, whereas there is no clear electrostatic preference at
positions 3 and 7 or most of the ribose moiety, except perhaps a preference for a positive charge
at the 2’-position. Large substitutions are indicated as unfavorable in positions 1, 2, 8 and 2’, and
at the 6-amino group of adenosine (Figure 5, yellow indicators), but the position of the ribose
group does not appear to be restricted with respect to further expansion/elongation, in line with
the positioning and high affinity of the long diamidines.

The above interpretation of the CoMFA and CoMSIA models is entirely consistent with
the experimentally obtained G0 values listed in Supplemental Table 1 (Appendix A). For
37

instance the importance of the partial negative charge on position 1, presumably as hydrogen
bond acceptor, is demonstrated by the reduced affinity of 1-deazaadenosine versus adenosine
((G0) = 9.7 kJ/mol) and of 1-deazapurine versus purine ((G0) = 4.9 kJ/mol). Similarly, the
positive charge provided by the 6-position amine is quantified by comparison of purine riboside
with adenosine ((G0) = 7.3 kJ/mol), purine with adenine ((G0) = 10.2 kJ/mol) and 6chloropurine riboside with adenosine ((G0) = 7.0 kJ/mol). As shown in Figure 7, this gives
estimates of contributions of 9.7 and 8.2 kJ/mol for the N1 and 6-amino groups, respectively.
The loss of both these groups should thus result in a loss of binding energy of approximately 16
kJ/mol and this was demonstrated by comparing 2’-deoxyinosine with 2’-deoxyadenosine
((G0) = 16.3 kJ/mol) and 1-deazapurine with adenine ((G0) = 15.1 kJ/mol). The strong
contribution from N9 likewise follows from comparing 9-deazaadenosine with adenosine and
4,6-diaminopyrimindine with 2-aminopyridine ((G0) = 6.4 and 5.7 kJ/mol, respectively). The
relative unimportance of positions N3 and N7 was demonstrated using 3-deazaadenosine and 7deazaadenosine, respectively, as catalogued in Supplemental Table 2 (Appendix A), which also
lists relative affinities for compounds with substitutions at positions 2 and 8.

Finally, a substantial contribution to binding is made through interactions between the
aromatic purine or benzamidine moieties and amino acids in the transporter binding pocket,
through π-π stacking with aromatic residues, cation-π bonding or amino-aromatic interactions.40
Although this cannot be directly demonstrated by the use of “nonaromatic purines”, which would
have a completely different three-dimensional structure, uniquely for P2 this can be shown and
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quantified by comparing aromatic and nonaromatic diamidines (Supplemental Table 2, Appendix
A). The diagram in Figure 7 summarizes these data in the form of an interaction diagram
between P2 transporter and adenosine. This figure, gained from experimental data and using a
previously validated approach,1, 18 is in close agreement with data presented in Figure 5 based on
the predictive PLS regression model. It is important however to be clear that both modeling
approaches (Figures 5 and 7) are predictive with respect to substrate binding rather than
translocation, i.e. it does not predict transport efficiency for any individual substrate. This
limitation is not inherent to the computational approach, rather it is the result of using Ki values
(transport inhibition through extracellular binding) instead of Michaelis-Menten constants (Km
and Vmax values, determined from measurement of transport) as input for the models. A similar
approach as followed here could predict transport, but it would have required radiolabeled
analogues of all the compounds used in the study, and this was not feasible. We also would not
wish to suggest that efficient uptake by a pathogen is sufficient to ensure efficacy of a potential
therapeutic agent, as this requires optimal interaction with the intended intracellular target as
well. In summary, we have developed and validated a novel computational approach to analyze,
explain, and predict the interactions between transporters and their substrates that does not
require prior knowledge of transporter structure or indeed primary sequence.
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Tables and Figures

Table 1. CoMFA and CoMSIA model statistics for the datasets A-D of Figure 2.
CoMFA
A

B

C

D

Total Compounds

36

29

16

16

n

7

4

5

2

q2cv

0.65

0.55

0.57

0.79

SEE

0.29

0.32

0.17

0.12

r2

0.93

0.89

0.98

0.99

F

55.9

50.5

74.4

311
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36
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16

16

n
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3

3

2

q2cv

0.50
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0.65

0.61

SEE

0.32

0.34

0.26

0.11

r2

0.91

0.86

0.93

0.99

F

62.5

51.5

47.4

358

CoMSIA
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Table 2. CoMFA and CoMSIA model statistics for the 112 compound database.
CoMFA

CoMSIA

Total Compounds

112

112

n

11

6

q2cv

0.55

0.54

q210-Fold

0.56

0.54

SEE

0.22

0.37

2

r

0.95

0.86
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Figure 1. Scaffolds for initial alignment: A, adenine; B, furamidine; C, stilbamidine; D,
pentamidine; E, 1,1’-(nonane-1,9-diyl)diguanidine; F, melarsoprol; G, isometamidium. All 112
compounds could be aligned to one of these scaffolds. Most compounds were in A-D.
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A

B

C

D

Figure 2. First alignment processes produced seven different databases for the 112 compounds.
The compounds of the larger datasets, A-D, were employed for QSAR CoMFA and CoMSIA
studies. Resulting three-dimensional CoMFA molecular surfaces are shown for datasets A-D,
which are labeled A-D, respectively. Steric contributions are shown in green (favors bulky
substituents) and yellow (bulky substituents impact negatively on binding), and the electrostatic
contributions are displayed in blue (favoring a positive charge) and red (favoring a negative
charge).
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A

B

Figure 3. Final alignment of 112 compounds, with adenine displayed in purple.
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Figure 4. Actual versus predicted results from PLS models employing CoMFA (left) and
CoMSIA (right) molecular descriptors.
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1

Figure 5. Calculated three-dimensional molecular surfaces for analyses of compound structural
relationships with P2 transporter inhibition. From left to right, the compounds shown above are
2-aminopyridine, 4,6-diaminopyrimidine, adenine, and adenosine. Colors are as in Figure 2.
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Figure 6. Three-dimensional molecular surfaces for pentamidine (top), furamidine (middle), and
melarsoprol (bottom). Colors are as in Figure 2.
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Figure 7. Model of adenosine, giving estimates of the contributions to the total binding energy of
34 kJ/mol in the black numbers, with the red numbers indicating the position on the purine or
ribose rings. The half-circles indicate positions where substitutions reduced the adenosine
binding affinity. The aromatic rings are estimated to contribute approximately 12 kJ/mol to the
binding energy, although this could not be verified directly, as a nonaromatic adenosine analog
would have a completely different three-dimensional structure. However, comparisons between
aromatic diamidines and nonaromatic diamidines (Supplemental Table 2, Appendix A) are
consistent with this estimate.
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A dataset of 55 compounds with inhibitory activity against L. donovani axenic
amastigotes and L. amazonensis intracellular parasites was examined through three-dimensional
quantitative structure-activity relationship modeling employing molecular descriptors from both
rigid and flexible compounds. For training and testing purposes, the compounds were divided
into two datasets of 45 and 10 compounds, respectively. Statistically significant models were
constructed and validated via the internal and external predictions. For all models employing
steric, electrostatic, hydrophobic, H-donor and H-acceptor molecular descriptors, the R2 values
were greater than 0.90 and the SEE values were less than 0.22. The models obtained from rigid
and flexible compounds were employed together to obtain a conservative method for predictions.
This method minimized under predictions. Molecular descriptors from the models were then
extrapolated, for the overall predictive devices and the individual compounds, and examined
with regard to inhibitory activity. Information gained from the molecular descriptors is useful to
the design of novel compounds. The models obtained can be employed to predict activities of the
compounds designed and/or form predictions for compounds that exist and have not yet been
examined with biological inhibitory assays.
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Introduction

Leishmania species cause leishmaniasis, which is an endemic disease found in tropic and
subtropic regions riddled with poverty and neglect.1-3 This infection is most often in the form of
cutaneous leishmaniasis, visible skin sores, or visceral leishaniasis, affected internal organs.
Primarily transported through the bite of a female phlebotomine sandfly, millions of new cases
are reported annually.1, 4 When untreated, tens of thousands of these parasitic infections result in
death.

Primary treatments for leishmaniasis include sodium stibogluconate and

N-

methylglucamine, while secondary therapies, which are often toxic, include pentamidine
isethionate, amphotericin B and paromomycin sulfate.1, 5 These classic treatments are costly and
embedded with implications of high toxicity, resistance, pain, nausea, and diarrhea. Possible new
therapies for the treatment of leishmaniasis have been examined and these include the
implementation of liposomes, natural products, synthetic compounds and vaccines.1,

6

Most

methods employing liposomes are costly and hence not feasible, while other methods of therapy
improvement have showed promice.1,

7

Several natural products and synthetic compounds

possess better therapeutic profiles with regard to activity and toxicity than the compounds
currently used in treatment, while vaccine development has been too specific to Leishmania
species and thus unsuccessful.1

59

Through several research endeavors activities and toxicities of series of compounds have
been gathered and such data have been implemented in rational drug design.8-11 These studies
employ biological data of natural and/or synthetic compounds and computational tools to
examine compounds with activity against Leishmania species. Examination of such compounds
has led to the formation of predictive devices and from these devices the importance of some
molecular structures has been ascertained. Although specific receptor interaction studies are
important, especially when studying mechanisms, intact parasite studies of inhibition and
toxicity are crucial for identifying compounds that will eradicate the parasite from hosts. 1 Such
studies of synthetic chalcones and phospholipids display effective antileishmanial activity for
compounds with: (1) a long alkyl chain, (2) bulky group’s terminal the alkyl chain, and (3) an
electron deficient group.9, 12

Our studies examine a biological dataset of synthetic arylimidamides which possess
activities against L. donovani axenic amastigotes and L. amazonensis intracellular parasites.
Inhibitory data, in the form of IC50 values, and Comparative Molecular Field Analysis (CoMFA)
and Comparative Molecular Similarity Indices Analysis (CoMSIA) molecular descriptors were
employed for partial least squares (PLS) regression. Predictive models and resulting molecular
descriptor potentials contribute to the identification and understanding of important molecular
features that govern the inhibitory actives of arylimidamides against species of Leishmania.
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Experimental Procedures

Inhibitory Data. Briefly, IC50 (µM) values were gathered for compounds of interest using
two assays. The first assay screened against axenic amastigote-like L. donovani, while the second
screened against L. amazonensis intracellular parasites. Screening against L. donovani was
conducted by: (1) culturing Ld1s parasites in potassium-based medium at pH 5.5, 37 °C, (2)
incubating for three days with compounds in a 96-well plate, and (3) adding tetrazolium dye and
quantifying the assay spectrophotometrically. While screening against L. amazonensis
intracellular parasites was conducted by: (1) plating macrophages and allowing adhering
overnight, (2) adding L. amazonensis promastigotes transfected with β-Lactamase gene (MOI:
5:1) and incubating overnight, (3) adding compounds of interest and incubating for 72 hours at
the temperature of interest, (4) adding nitrocefin in lysis buffer and incubating an additional 3 to
5 hours, and (5) reading the plate at 490 nm.13 Experimental IC50 values for L. donovani axenic
amastigotes and L. amazonensis intracellular parasites were obtained for 55 compounds.

Preparation of Compounds for Computational Studies. SYBYL 8.114 software was
employed to construct all compounds in three-dimensional space. Compounds were then divided
into training and testing datasets. These datasets consisted of 45 and 10 compounds, respectively.
The compounds of the training dataset then underwent a short molecular dynamics simulation of
1 ns. This system employed SYBYL 8.1 default settings at a constant temperature and volume
(NTV). Briefly, (1) the system temperature was 300K with a coupling constant of 100 fs, (2)
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Maxwell-Boltzmann distribution was employed for initial atom velocities, (3) the non-bonded
pair list was updated every 25 fs, (4) and the duration of the molecular dynamics simulations in
vacuo was 1ns with a time step of 100 fs and a snapshot every 1000 fs. This displayed several
low energy structures. Torsional angles of all training dataset compounds were modified to
explore the low energy conformations and modified compounds were minimized to convergence
using the Tripos force field, conjugate gradient algorithm, and Gaseiger-Huckel charges. The
termination gradient was 0.01 kcal/(mol Å) and the maximum iterations were 104.

Rigid Alignment of Compounds and Resulting Models. Each training dataset of
compounds with modified torsional angles was aligned using the “Align Database” option of the
QSAR module in SYBYL. Aligned structures were then analyzed through the use of molecular
descriptors. CoMFA (steric and electrostatic) and CoMSIA (steric, electrostatic, hydrophobic,
H-donors and H-acceptors) molecular descriptors were calculated and PLS regression was
employed to compare the molecular descriptors of compounds to obtained average IC50 values.
The number of components was determined by the smallest predicted error sum of squares.
Optimum models employing CoMFA molecular descriptors consisted of three components,
whereas the ones with CoMSIA molecular descriptors employed six.

Flexible Alignment of Compounds and Resulting Models. Five compounds with low IC50
values for the L. amazonensis intracellular parasite assay were employed for flexible compound
alignment using the “Align Pharmacophore” option of the GALAHAD module. Parameters were
acquired through the “Suggest from Data” option and the best 20 models were gained. The
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highest scoring model with respect to maximized pharmacophore consensus, maximized steric
consensus, and minimized energy was employed as a template for individual compound
alignment of the entire training dataset. The “Align Molecules to Template Individually” option
was selected and parameters were acquired once more through the “Suggest from Data” option;
the “Keep Best N Models” option was reset to 20. Molecular descriptors were calculated for the
highest scoring model and PLS regression was implemented in the same manner as for the rigid
compounds. The optimum numbers of components were determined as previously described;
models with CoMFA molecular descriptors consisted of three components, whereas models with
CoMSIA molecular descriptors employed six.

Statistical Analyses. The statistics calculated from PLS regression included: a crossvalidated correlation coefficient (Q2), the coefficient of determination (R2), the standard error of
estimate (SEE), the F statistic, a bootstrap R2 (R2bs), and a bootstrap SEE (SEEbs). The bootstrap
analysis was used to check the stability of the models through cross-validation into two, five, and
ten groups. The average values of the bootstrap analysis are displayed with the rest of the
statistics.

Testing Datasets and the Conservative Model Method. The models constructed from the
rigid and flexible alignments were employed to examine testing datasets that were aligned via
rigid and flexible methods. Of the pIC50 values predicted, for both training and testing datasets,
the more negative pIC50 prediction was considered the most viable. This method favors over
prediction rather than under prediction.
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Molecular Descriptor Potentials. Molecular descriptor potentials acquired through the
mapping of the product standard deviation with respect to molecular descriptor values and
coefficients at each lattice point were extrapolated from the models. Default levels of contour by
contribution were employed to gather favored and disfavored potentials for overall models. The
individual compounds of the models were analyzed via the contour by actual analysis method.
Software output was used to determine the proper ranges of assigned favored and disfavored
contour regions for individual compounds.

Results

The entirety of the dataset, 45 training and 10 testing compounds, can be represented via
the scaffold structure displayed in Figure 1. At each of the five positions labeled in this figure
there are differing atoms or groups: positions one and four display single atom changes in the
form of carbon, oxygen, sulfur, and nitrogen, whereas positions two, three and five display larger
group substituent modifications.

Biological IC50 values were acquired for each compound of the training and testing
datasets through two assays targeting L. donovani axenic amastigotes and L. amazonensis
intracellular parasites. These inhibitory values were averaged and standard deviations were
acquired (Supplemental Table 3, Appendix B and Table 3). For modeling purposes, the IC50
values were log transformed into pIC50 values (pIC50 = −log(IC50)). Figure 2 displays the pIC50
data; experimental values against the L. donovani axenic amastigotes are shown in green,
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whereas the values against the L. amazonensis intracellular parasites are displayed in blue. The
standard deviations of the data are represented in general by trend lines and the averaged values
are shown as triangles and squares, respectively. Notice that the slopes are very similar with
values between 0.96 and 1.0, and R2 values are 0.95 or higher. This displays the relative range of
inhibitory activity and respective deviations from the average inhibitory values associated with
each synthetic compound in the training and testing datasets. The pIC50 distribution of data are
also shown in this figure; the inhibitory activity of arylimidamides against L. donovani axenic
amastigotes ranges between approximately -2.5 and 0.5, whereas those active against L.
amazonensis intracellular parasites range between about -1.5 and 1.5.

Compounds examined through biological assays were aligned in silico in threedimensional conformations using two methods: (1) rigid alignments of compounds were
obtained through the implementation of the SYBYL “Align Database” option of the QSAR
module, and (2) flexible alignments of compounds were acquired through the use of the
“Pharmacophore Alignment” option of the GALAHAD module. Rigid alignments were
preformed on low energy conformations of compounds. Molecular descriptors were then
calculated and PLS regression was employed to construct predictive models implementing the
descriptors and respective biological inhibitory data. The best computational models formed
consisted of compounds in their most linear conformation with an overall plus one charge.

Flexible alignment of compounds was also implemented. This process employed the five
most active compounds against the L. amazonensis intracellular parasites from the training
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dataset (Figure 3). Figure 4 displays the outcome of pharmacophore simulations that lead to PLS
regression models employing flexible compounds. The rotation of the compounds allows for
visualization of alignment and positioning of identified feature potentials. The observed features
governing structure alignment are: (1) four aromatic rings (cyan); (2) N=C−N groups, two
positive nitrogen (red) and a H-donor (magenta); (3) atoms at the one and a two position of
Figure 1, two H-acceptor (green); (4) atoms at a five position, a H-donor or H-acceptor (overlaid
magenta and green equates to dark green). Then, all of the training and testing compounds were
flexibly aligned to the pharmacophore. These alignments can be viewed in relation to rigid
alignments (Figure 5). Rigid compounds were aligned by N=C−N groups. Notice that there is a
difference in the spatial relationships of the compounds.

Inhibitory and compound structural data were employed to construct predictive models
through PLS regression methods. The statistics for these models indicate that models employing
CoMSIA molecular descriptors should outperform those constructed with CoMFA molecular
descriptors (Table 1). This is shown in higher Q2, R2, and F statistics and lower SEE statistics for
the models constructed with rigid compounds. Similarly, the models of flexible compounds
displayed higher R2 and F statistics and lower SEE statistics. The low Q2 values for models of
flexible compounds were attributed to: (1) torsional variability, (2) differences in optimal low
energy structural conformations, and (3) contributions of compound inhibitory activities. Based
on statistics, models with CoMSIA molecular descriptors were examined further with regard to
molecular descriptors (Table 2). The factors governing these models were dominated by
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hydrophobic potentials followed by H-donor potentials. Smaller contributions were made by Hacceptor, steric, and electrostatic potentials, respectively.

The internal (training dataset) and external (testing dataset) predictions of these models
are displayed in Figure 6 through the plotting of predicted pIC50 values in relation to
experimental pIC50 values. The training dataset of this figure is colored in accordance to Figure
2, whereas all testing dataset predictions are in red. Although internal predictions were linear,
some testing dataset compounds were more difficult to predict for than others. The variance in
compound prediction differed between the models for compounds of rigid and flexible
alignments; hence, by taking the most negative prediction of each compound regardless of rigid
or flexible alignment and plotting these values against respective experimental data a
conservative method for prediction can be obtained. The combination of the models reduces
under prediction. Table 3 displays the testing dataset along with experimental average IC50
values, plus or minus respective standard deviations, along with the conservative model IC50
prediction; note that model error for each compound is not shown.

From the models employing CoMSIA molecular descriptors, potentials were extrapolated
and viewed in relation to the overall models (Figure 7) and individual compounds thereof (Figure
8). Figure 7 displays the overall CoMSIA molecular descriptors for the rigid and flexible models.
It is evident that each overall model displays different molecular descriptor potential
contributions, for all molecular descriptors (steric, electrostatic, hydrophobic, H-donor and Hacceptor). This indicates that each model is constructed somewhat differently; although, there are
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similarities between the potentials obtained. Using the positions of Figure 1 as a reference: (1)
steric bulk is favored (green) at positions three and five and perhaps not symmetrically, whereas
disfavored steric bulk (yellow) regions are just outside those favored, (2) positive electrostatic
charge is favored (blue) at one, if not both, of the N=C−N groups near position five, whereas
negative charge is favored (red) predominantly at or near position one and outside one of the
N=C−N groups, (3) hydrophobic interactions are favored (yellow) at positions two and five,
whereas disfavored hydrophobic interactions (gray) are near three positions and outside five
positions, (4) H-donor atoms are favored (cyan) predominantly at or below the five position and
disfavored (purple) in regions beyond favored regions and on three positions, and (5) Hacceptors are favored (magenta) near the terminal N=C−N groups, and disfavored (red) below
the four position(s) and outside favored N=C−N groups of the comparison molecule DB766.

With regard to the scaffold structure of Figure 1, Figure 8 displays the molecular
descriptor potentials of individual compounds extrapolated from respective models employing
CoMSIA molecular descriptors. The molecular descriptor potential regions of individual
molecules appear to be more consistent within their respective rigid and flexible models than
they were in the overall models of Figure 7. However, the molecular potentials that resulted were
also fewer. These included favored and disfavored hydrophobic, favored H-donor and favored Hacceptor potentials. With X of Figure 8 representing positions one through five of the Figure 1
scaffold structure and biological inhibitory data in Supplemental Table 3 (Appendix B), it is
possible to examine not only the molecular descriptor potentials with regard to model
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contribution but also the contribution of substructures to biological inhibitory activity. To most
effectively describe these findings, it is important that comparisons are made to a compound that
is active in both datasets. DB766 was selected for analyses.

With respect to Figure 1, the molecular descriptor potentials for DB766 include: (1)
favored hydrophobic potentials near the aromatic rings consisting of the four position, opposite
position three, and on the flanking five position aromatic rings, (2) favored H-donor potentials
are displayed below the left five position N=C−N group, and (3) favored H-acceptor potentials
are on the N=C−N group opposite the side of the favored H-donor and extended to the outer
aromatic ring. The IC50 values for this compound against L. amazonensis intracellular parasites
and L. donovani axenic amastigotes are 0.09 and 0.50 µM, respectively. The general structure of
DB1867, compared to DB766, differs only by a sulfur atom at position one and with this change
the compound becomes more linear and favored hydrophobic interactions are spread to positions
one and two. Potentials for favored H-acceptors are near N=C−N groups and the IC50 values are
0.05 and 0.68 µM, respectively. DB946 is the only compound in the training dataset to differ
from DB766 at position two; this compound also differs at position three. The methyl groups at
position two fill similar special areas as substituents in position three. Favored hydrophobic
potentials reside in position two, three, and five locations. This compound’s IC50 values are 0.11
and 0.37 µM, respectively. DB667 and DB1876 differ from DB766 at position three. DB667
consists of hydrogen atoms at position three and molecular descriptor potentials similar to those
of DB946 (hydrophobic) and DB766 (H-donor and H-acceptor); although, the favored
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hydrophobic potentials span a greater length for DB667. The IC50 values for this compound are
0.53 and 1.6 µM, respectively. DB1876 displays large disfavored hydrophobic molecular
descriptor potentials at the three positions. The remaining potentials are favored hydrophobic
potentials near the aromatic rings and favored H-donor and H-acceptor potentials near the
N=C−N group(s). This compound has IC50 values of 2.1 and 28 µM, respectively. DB1851
differed from DB766 at position four. This resulted in favored hydrophobic interactions that span
more of the molecule than previous compounds discussed and H-donor and H-acceptor potentials
similar to those of DB1876. The IC50 values for these compounds are poor, greater than 10 and
50 µM, respectively. DB1921, DB1942, and DB1906 all differ from DB766 at the five positions.
DB1921 is flanked at the five positions and has different substituents at the three positions. This
compound consists of potentials similar to DB1876; however, it is also missing most of the
favored hydrophobic and H-acceptor potentials. The IC50 values for this compound are 4.7 and
41 µM, respectively. DB1942 consists of a longer more flexible ring structure than DB766 and
consists of disfavored hydrophobic molecular descriptor potentials primarily at the five positions.
Positive hydrophobic potentials are on the inner aromatic rings or the outer rings near the five
position, whereas H-donors are favored on one side of a N=C−N group and H-acceptors are
favored at both N=C−N group(s). This compound has IC50 values of 0.81 and 3.6 µM,
respectively. The five positions of DB1906 consist of more rings than DB766. The molecular
descriptor potentials for this compound were similar to those of DB766 (hydrophobic and Hdonor) and DB946 (H-acceptor), IC50 values are 0.27 and 1.9 µM, respectively.
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Discussion

Studies examined chalcones and phospholipids and found that high inhibitory activity
occurred when compounds possessed a long alkyl chain, bulky groups terminal the alkyl chain,
and an electron deficient group.9,

12

The structures of chalcones and phospholipids are quite

different from each other, and these compounds differ substantially from the arylimidamides
examined in this study (Figure 1 and Supplemental Table 3, Appendix B).

The numbered locations of Figure 1 aid in the explanation of inhibitory data displayed in
Figure 2 through the interpretation of pharmacophore consensus potentials (Figure 4) and
molecular descriptor contribution potentials (Figures 7 and 8). The pharmacophore alignment of
Figure 4 is calculated using the compounds of Figure 3. By only employing the most active
compounds, the pharmacophore is strictly for compounds of similar structure and inhibitory
activity. The pharmacophore results suggest importance of aromatic and positively charged
N=C−N groups. These can be related to the bulky groups flanking the alkyl chain and the
electron deficient group, respectively. The long alkyl chain may be related to the long carbon
backbone that is in part aromatic groups and/or the carbons of the furan that link the rings.

PLS regression of calculated molecular descriptor potentials and respective biological
inhibitory values, for both the rigid and flexible alignments of compounds presented in Figure 5,
produced statistically significant models; yet, those employing the CoMSIA molecular
descriptors from rigid structure alignment were the only ones with Q2 values greater than 0.5
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(Table 1). It has been stated for years that if Q2 values are greater than 0.5 then the model has
predictability better than chance.14 What we realize from our models, especially those aligned by
flexible conformations, is that each compound contributes to the entirety of the model and that
the models constructed from molecular descriptors of flexible compounds may be predicting just
as well, if not better, than those constructed from molecular descriptors of rigid compounds
(Figure 6). The rigid models of Figure 6 produce a greater amount of under prediction than the
flexible models. For example, for the rigid model, one of the compounds active against L.
donovani has an experimentally determined pIC50 value of -1.7 and a predicted value of 0, these
IC50 values are 50 and 1, respectively, whereas for the flexible model the same compound has a
predicted pIC50 value of -1.7, the same as the experimental value.

Under prediction is a problem that needs to be addressed since predictive models such as
the ones constructed in this study can be employed to scan potential candidates for synthetic drug
design. Often synthetic measures are costly and timely; hence, it is better to synthesize only
compounds expected to have the best inhibitory activity and disregard those expected to have the
worse. To minimize under prediction, the minimum pIC50 predictions from the rigid or flexible
models were plotted against the average experimental values. These data are shown as the
conservative predictions of Figure 6. In this column we see that under predictions are no longer
occurring for these models; yet, there are still over predictions. Over predictions, as long as they
are few, are not as problematic since these values are larger and synthetic measures will most
likely result in biologically obtained inhibitory activity better than calculated.
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From models, such as the ones constructed during this study, molecular descriptor
contributions can be obtained and observed. A previous study that employed CoMSIA molecular
descriptors found that steric and hydrophobic interactions governed the model.9 This study was
for synthetic phospholipids. Similarly, our model was governed by hydrophobic interactions; yet,
this contribution of molecular descriptor interactions was followed by H-donor, H-acceptor,
steric and then electrostatic (Table 2). When the overall CoMSIA potentials for each molecular
descriptor are visualized, compound structures appear applicable for modifications. Figure 7
allows for comparison between the models and overall analyses. It is important to realize that
molecular descriptor potentials are unique to each model; hence, no two models are the same. As
was found important previously, positive blue electrostatic potentials display the importance of
the N=C−N groups, whereas the steric and hydrophobic potentials show the importance of the
rings and substituents. To fully understand molecular descriptor contribution in relation to
biological inhibitory data, it is important to analyze the potentials of individual compounds; a
select set of which are shown in Figure 8. These potentials display much more consistency than
those for the overall models of Figure 7.

New compounds can be designed by employing the data acquired from the
pharmacophore (Figure 4) and extrapolated molecular descriptor potentials (Figures 7 and 8). To
do this, the basic pharmacophore must remain intact and the potentials of the overall models and
those of individual compounds should be used for guidance. Since the importance of
hydrophobic, H-donor and H-acceptor atoms are clearly displayed as essential potentials for the
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individual compounds in Figure 8; this is a good place to begin. The favored hydrophobic
potentials of the four aromatic rings exhibit significance (Figures 7 and 8); these are also seen as
important in the pharmacophore (Figure 4). Hence, it appears imperative that the four rings
remain a constant in our initial modeling efforts. H-donors appear to be important to regions near
the N=C−N groups (Figures 7 and 8). One of the N=C−N groups is shown as essential in the
pharmacophore (Figure 4). Likewise, H-acceptors appear to be significant to the region including
and between the N=C−N groups and the N of the outer most aromatic rings (Figures 7 and 8).
One such region was identified in the pharmacophore (Figure 4). Based on these observations,
new compounds have been designed and predictions have been obtained (Figure 9). The ranges
include the smallest and largest prediction obtained via the models constructed of rigid and
flexible compound structures.

In summary, by employing such findings it is possible to scan for potentially active
compounds both efficiently and conservatively through the use of predictive models. The
governing of inhibition results as models are employed and new compounds are designed,
activities are predicted, compounds are synthesized, and biological assays provide experimental
data for analyses.
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Tables and Figures

Table 1. Statistics of partial least squares predictive models for a biological dataset of synthetic
arylimidamides with activities against L. donovani axenic amastigotes (LD) and L. amazonensis
intracellular parasites (LA).

Q2
SEE
R2
F
SEEbs
R2bs

Rigid Alignment
CoMFA
CoMSIA
LA
LD
LA
LD
0.23
0.25
0.47
0.59
0.45
0.41
0.25
0.18
0.68
0.77
0.91
0.96
29.1
44.5
61.4
137
0.35
0.37
0.21
0.16
0.80
0.82
0.94
0.97

Flexible Alignment
CoMFA
CoMSIA
LA
LD
LA
LD
0.16
0.60
0.07
0.22
0.24
0.33
0.16
0.14
0.91
0.85
0.96
0.97
131
78.0
159
229
0.21
0.26
0.12
0.12
0.93
0.90
0.98
0.98
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Table 2. Contribution of CoMSIA molecular descriptors for rigid and flexible models employing
structures of training dataset compounds and respective biological activities.

Steric
Electrostatic
Hydrophobic
H-Donor
H-Acceptor

Rigid Alignment
L. amazonensis
L. donovani
0.15
0.14
0.11
0.08
0.47
0.43
0.15
0.21
0.12
0.14
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Flexible Alignment
L. amazonensis
L. donovani
0.13
0.13
0.14
0.15
0.33
0.34
0.20
0.21
0.20
0.17

Table 3. Predictions in terms of IC50. Experimental values for compound inhibitory activity
against L. donovani axenic amastigotes (LD) and L. amazonensis intracellular parasites (LA) are
displayed in columns LD Calc and LA Calc. The predicted values are those from the
conservative predictions of Figure 6.
Name
DB710

Structure

LA Exp
LA Calc LD Exp LD Calc
1.4
0.16 ± 0.04
0.84 ± 0.2
4.0

DB712

0.56 ± 0.08

0.65

2.0 ± 0.6

4.6

DB749

3.1 ± 0.7

1.4

>50

50

DB874

1.4 ± 0.3

0.66

4.2 ± 1.3

3.2

DB889

0.11 ± 0.02

2.3

1.7 ± 0.5

10

DB1856

0.74 ± 0.3

3.2

5.8 ± 0.7

10

DB1857

0.37 ± 0.2

0.69

1.0 ± 0.2

10

DB1864

>10

9.3

5.6 ± 1.8

16
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Table 3 (continued)
Name
Structure
DB1908

LA Exp
>10

LA Calc
4.7

LD Exp
14 ± 1

LD Calc
16

DB1930

5.5 ± 0.2

9.3

>100
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Scaffold Structure 1. Backbone of
47 training and all 10 testing
through quantitative structure-activity relationships of L. donovani axenic amastigotes and L.
compounds.
amazonensis
intracellular parasites. All training dataset structures and respective inhibitory data
Figure 1. Scaffold structure for compounds being employed to examine biological inhibitory data

can be viewed in Supplemental Table 3 (Appendix B).

Scaffold Structure 3. Backbone of
DB1881, DB1882, and 1910.

Scaffold Structure 823. Backbone
of DB1911 and DB1945.

1.5

0.5

y = 0.96x - 0.11
R² = 0.98

y = 0.98x - 0.08
R² = 0.99

y = 0.97x + 0.13
R² = 0.95

-0.5

-1.5

-2.5
-2.5

y = 1.0x + 0.11
R² = 0.99

-1.5
-0.5
0.5
1.5
Experimental pIC50 Values

Figure 2. Biological pIC50 data of synthetic arylimidamides active against L. donovani axenic
amastigotes (green) and L. amazonensis intracellular parasites (blue). The negative log values of
average experimentally obtained IC50 data, displayed in Supplemental Table 3 (Appendix B) and
Table 3, and these values plus and minus respective standard deviations are all plotted against the
negative log value of average experimentally obtained IC50 data.
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DB1867

DB766

DB946

DB745

DB1862

Figure 3. Five of the most active compounds against L. amazonensis intracellular parasites and L.
donovani axenic amastigotes.

84

Initial
View

+90

+180

+270

Figure 4. GALAHAD potentials as identified by simulations employing the compounds of
Figure 3. The identified features are color coded: cyan, hydrophobes; magenta, donor atoms;
green, acceptor atoms; red, positive nitrogens.
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Flexible Alignment

Rigid Alignment

Figure 5. Final training (top) and testing (bottom) datasets: flexible alignments (left) and rigid
alignments (right).
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Predicted Value (pIC50)

Rigid

Flexible

1.5

Conservative

1.5

1.5
L. amazonensis

-1.5
-1.5

1.5

-1.5
-1.5

0.5

-2.5

-1.5
-1.5

-2.5

1.5

0.5

0.5

0.5
-2.5

1.5

0.5

-2.5

0.5

L. donovani

-2.5

-2.5

Experimental Value (pIC50)
Figure 6. Internal (blue and green) and external (red) predictions. The internal predictions are
those for the training dataset compounds implementing the model constructed, whereas external
predictions are those for the testing dataset compounds. The models have never seen the testing
datasets. The L. amazonensis experimental versus predicted results are shown in blue above
those for L. donovani in green. The experimental versus predicted results from left to right are
predictions from implementing rigid (left) and flexible (center) compounds. The conservative
predictions (right) are essentially the more negative of the two pIC50 predictions resulting from
the models with rigid and flexible compounds. Since the scale observed is the negative log of the
IC50, this method reduces under prediction.
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Figure 7. Overall models with CoMSIA molecular descriptors for both rigid and flexible
compound alignments. DB766 is displayed as a reference compound for each molecular
descriptor potential. Favored potentials from steric to H-acceptor molecular descriptors are
green, blue, yellow, cyan, and magenta, whereas disfavored potentials from steric to H-acceptor
molecular descriptors are yellow, red, gray, purple, and red.
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X
0

Compound
DB766

1

DB1867

2

DB946

L. amazonensis
Rigid
Flexible

L. donovani
Rigid

Flexible

3a DB667

3b DB1876

4

DB1851

5a DB1921

5b DB1942

5c DB1906

Figure 8. CoMSIA findings with respect to Figure 1 and molecular descriptor potentials of
Figure 7. The favored hydrophobic potentials have been changed to orange to improve
visualization and insure that steric potentials were not displayed. The left most column consists
of numbers correlated to positions of Figure 1. The column to the right consists of the
compounds name. This is followed by the compounds and their respective molecular descriptor
potentials for each the final models.
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Figure 9. Compounds designed using the pharmacophore data of Figure 4 and the CoMSIA
molecular descriptor fields of Figures 7 and 8. The structures of the compounds are to the left of
the predicted IC50 ranges. Ranges of predicted IC50 values were acquired through the use of both
models constructed of rigid and flexible compounds.
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Trypanosoma cruzi, which affects millions of people in endemic areas of Latin America,
is the etiological agent of Chagas disease. The available therapy is not ideal since it presents
limited efficacy, especially in chronic patients, and displays considerable side effects; thus the
need for new trypanocidal compounds is indisputable. In vitro assays have been used to
determine the biological activities of diamidines and arylimidamides against T. cruzi at two
tempertures relating to that of blood stored at blood banks (4°C) and that of the human body
(37°C). Our studies employ the corresponding biological IC50 values acquired to examine
compound structural importance through computational biology. Hence, a pharmacophore was
identified and implemented to assess quantitative structure-activity relationships (QSAR)
through partial least squares (PLS) regression modeling employing the biologically obtained IC50
values and computationally calculated comparative molecular field analysis (CoMFA) and
comparative molecular similarity indices analysis (CoMSIA) molecular descriptors. Statistically
significant models were acquired; these models have Q2 values greater than 0.51 and R2 values
greater than 0.94. Models were internally and externally validated and the molecular descriptor
potentials were extrapolated for overall models. The computational data acquired can be used to
screen for compounds with inhibitory activities against T. cruzi and design novel therapeutic
agents.
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Introduction

Trypanosoma cruzi is the protozoan parasite that causes Chagas disease (CD), a tropical
illness that affects 12-14 million people in many developing countries of Latin America and puts
about 50 million at risk of infection.1 The occurrence of CD in nonendemic regions such as the
United States and Europe is mainly due to the migration of infected people but also represents an
important concern in these areas.2-4

CD has two successive phases: a short acute phase characterized by patent parasitemia
followed by a long, progressive chronic phase. The acute phase starts shortly after the infection
and is often nonsymptomatic but may manifest as flu-like symptoms with a self-limited febrile
illness that lasts a few weeks. If untreated, the symptomatic chronic disease develops in about
20-40% of the infected individuals after a long latent period (several months and even decades),
while the majority of the patients remain in the indeterminate state.5,

6

Due to the long,

asymptomatic state, CD is considered a “silent killer,” impairing early specific diagnosis and
treatment.7 The main clinical chronic manifestations of CD include cardiac and/or digestive
alterations.8 CD is responsible for considerable rates of mortality and morbidity, however, in the
centennial of its discovery by Carlos Chagas (1909), no prophylactic or efficacious treatment is
available.9

Although they provide limited efficacy and activity upon different parasite stocks,
especially for the chronic sufferers, and cause deleterious side effects, the currently accepted
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clinical treatments for Chagas are Nifurtimox (Nfx) and Benznidazole (Bz); these two nitrogenbased compounds were introduced more than four decades ago.10, 11 Thus, the limitation of the
current treatment for CD justifies the search and screening of other drugs that could replace Nfx
and Bz and/or could be used in cases of therapeutic failure.12

Aromatic synthetic diamidine (DA) and arylimidamide (AIA) compounds have been
identified as potential therapeutics for CD.9,

12-22

Our biological assays for DA and AIA

compounds have resulted in inhibitory activity assessment for 47 compounds at temperatures of
4°C, the temperature of blood stored in blood banks, and 37°C, the temperature of the human
body. In this study, the data from our biological assays were employed to develop predictive
models and examine the structural importance of these compounds at the two temperatures. A
pharmacophore for active compounds was acquired and implemented in quantitative structureactivity relationship (QSAR) examination through partial least squares (PLS) regression
modeling employing biologically obtained inhibitory values, in the form of IC 50 data, and
computationally calculated comparative molecular field analysis (CoMFA) and comparative
molecular similarity indices analysis (CoMSIA) molecular descriptors. Subsequent to acquiring
statistically significant and validated predictive models, molecular descriptor potentials were
extrapolated from final models and employed along with the pharmacophore and predictive
models to gain insight into compound structural importance for the inhibition of T. cruzi.
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Experimental Procedures

Compounds. DA and AIA compounds were synthesized, and stock solutions were
prepared in dimethyl sulfoxide (DMSO) with the final concentration not exceeding 0.6%, which
did not exert any toxicity towards the parasite or mammalian host cells (data not shown).

Parasites. At peak parasitaemia, bloodstream trypomastigotes (BT; Y strain) were
harvested by heart puncture from T. cruzi infected Swiss mice as previously reported. All
procedures were carried out in accordance with the guidelines established by the FIOCRUZ
Committee of Ethics for the Use of Animals (approved protocol number: CEUA L-028/09).

Trypanocidal Analysis. IC50 values of 47 compounds were previously published.13-16, 18-21
These data were acquired through bloodstream trypomastigotes (BT) assays. Treatment entailed
different protocols as follows: BT (5 X 106 per mL) were incubated for 24 h at 37ºC in RPMI
1640 medium (Roswell Park Memorial Institute, Sigma Aldrich, USA) supplemented with 5%
FBS, in the presence or absence of serial dilutions of each compound (0 to 32 µM). Alternately,
experiments were performed at 4ºC with BT maintained in freshly isolated mouse blood (96%)
in the presence or absence of serial dilutions of the compound (0 to 200 μM). After drug
incubation, the parasite death rates were determined by light microscopy through the direct
quantification of the number of live parasites using a Neubauer chamber, and the IC50 values
were then calculated. The IC50 values were averaged for at least three determinations done in
duplicate.
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Computational Biology. All 47 compounds (41 training compounds and 6 testing
compounds) with IC50 values were constructed in SYBYL 8.123 on a Fedora Core 5 Linux
workstation. Structures for each compound were energy minimized to convergence using the
conjugate gradient method, Tripos force field, and Gasteiger-Hückel charges. The termination
gradient was 0.01 kcal/(mol Å) and the maximum iterations were 104. Compounds were then
semi-randomly separated into training and testing datasets of 41 and 6 compounds, respectively.
Compounds selected for the testing dataset represented the entirety of the dataset; they had
diverse backbones and biological activities.

The GALAHAD module in SYBYL was employed to gain a pharmacophore for
inhibitory compounds of the training dataset; four compounds (DB1831, DB1853, DB1868 and
DB766) with low IC50 values (Supplemental Table 4, Appendix C) were employed and the
parameters were acquired through the “Suggest from Data” option. The best model resulted in
maximized pharmacophore consensus, maximized steric consensus, and minimized energy. Due
to the structural diversity of compounds in the training and testing datasets, compounds were
aligned by the atoms of key features using the “Align Database” option of the QSAR module in
SYBYL. Identified important structural atoms were used as a template; DB766 was employed
for Cartesian coordinates. Compounds without the common structure were aligned by central
atoms that were similar.

PLS analyses employed the training datasets. Computationally calculated CoMFA and
CoMSIA molecular descriptors were calculated and mathematically modeled with respect to log
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transformed biologically acquired IC50 values; pIC50 = −log(IC50). Predictive models were
gained and implemented to predict pIC50 values for compounds of the training and testing
datasets. These models were then used to examine molecular descriptor contributions through
model extrapolated molecular potentials; visualization was attained by contribution through the
mapping of the product standard deviation with respect to molecular descriptor values and
coefficients (S.D.*Coeff.) at each lattice point. The default levels of the contour by contribution
were employed as follows: 80% for a favored region and 20% for a disfavored region.

Results

Inhibitory experimental assays against T. cruzi at 4°C and 37°C provided IC50 values for
47 compounds (Supplemental Table 4, Appendix C). All compounds with inhibitory data were
constructed in SYBYL and four compounds with low IC50 values, for both assays, were
employed for pharmacophore identification. It is important to note that the best inhibitory
compounds of this dataset are all AIAs. Given the structural variation of this dataset, only a
select set of features are applicable for the alignment of all compounds.

Figure 1 displays the pharmacophore potentials; structural importance appears to be
attributed to the central furan and its flanking aromatic rings. These rings are identified by
hydrophobe potentials. Using DB766 as a reference compound (Figure 2), Figure 1 also displays:
(1) a fourth hydrophobe potential residing on one of the isopropyl substituents, (2) donor
potentials at the N=C−N groups, (3) an acceptor potential on the furan O, as well as on both
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isopropyl O, and (4) a positive N potential at one N=C−N group. Perhaps the importance of the
one identified positive N comes from the net compound +1 charge of most AIAs. The
pharmacophore identification appeared to highlight the rigid central structure of the compounds;
the central structure is similar for AIAs and DAs.

Atoms representing the hydrophobe and acceptor potentials were identified and
implemented for training and testing dataset alignment; the atoms used in alignment are those
identified in Figure 2. An effective overlay of the 41 training and 6 testing compounds allowed
for three-dimensional compound comparison. The identified pharmacophore regions that were
not used for alignment were still maintained by AIAs (Figure 3). With compounds aligned,
CoMFA and CoMSIA molecular descriptors were calculated and these were employed along
with the experimentally obtained inhibitory values for QSAR studies with PLS modeling. The
models constructed have correlation coefficients (Q2) values greater than 0.51, standard error of
estimate (SEE) values lower than 0.29, coefficient of determination (R2) values greater than 0.94,
and large F statistics (Table 1).

Both CoMFA models consisted of approximately 70% steric and 30% electrostatic
molecular descriptor contributions, while the CoMSIA models exhibited more variation. The
model employing experimental inhibitory data at 4°C consisted of roughly 13% steric, 13%
electrostatic, 23% hydrophobic, 26% H-donor, and 25% H-acceptor contributions, whereas the
model with experimental inhibitory data at 37°C consisted of roughly 14% steric, 13%
electrostatic, 26% hydrophobic, 24% H-donor, and 23% H-acceptor contributions. The molecular
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descriptor contributions for both CoMSIA models were within 3% of each other; this difference
is not statistically significant. However, molecular descriptor contributions are related to the
weights that are employed by PLS to relate structural importance to inhibitory activity. This
relationship results in predictions. These molecular descriptor contributions suggest that
predictions from models employing CoMFA molecular descriptors will be more similar than
those from models employing CoMSIA molecular descriptors.

Figure 4 displays the training and testing dataset predictions for the PLS models;
trendlines are displayed for the training dataset predictions. Training data are displayed in blue
and green for the assays at 4°C and 37°C, respectively. Notice that the slopes of the trendlines
are all near one as expected for a valid model. Also, there are very few noticeable outliers.
Hence, the models should all be able to provide useful predictions for the compounds of the
testing dataset. This holds true according to the testing dataset predictions, the CoMFA model at
4°C and the CoMSIA model at 37°C are outperforming the other two models. The compounds of
the testing dataset can be viewed along with their experimental and predicted data in Table 2.
Notice that each of the testing compounds is quite different; they vary in size, shape, and
conformation. This allows for a full predictability range inspection based on compound structure.

The phenyl-pyridine DA DB1627 consists of accurate predictions, especially since the
inhibitory values for this compound are at an experimental cut-off. 10SAB031 is a DA that
consists of a triazole center ring and flanking aromatic rings, the amidines are in the m-position.
The models constructed of CoMFA molecular descriptors predicted better than those with
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CoMSIA molecular descriptors. DB1362 consists of a 3-bromo-4-methylthiophene central ring
and flanking aromatic rings. The amidines for this DA compound are in the p-position. The
model constructed of experimental data at 4°C and CoMFA molecular descriptors predicted best,
as did the model with experimental data at 37°C and CoMSIA molecular descriptors. 14SMB013
is a diamidine compound that has an aliphatic linker instead of a central ring. Again, the model
constructed of experimental data at 4°C and CoMFA molecular descriptors predicted best, as did
the model with experimental data at 37°C and CoMSIA molecular descriptors. AIA 613A, has a
scaffold structure similar to DB766; yet, this compound lacks isopropyl substituents and N in the
outer aromatic rings. As before, the model constructed of experimental data at 4°C and CoMFA
molecular descriptors predicted best, as did the model with experimental data at 37°C and
CoMSIA molecular descriptors. DB1868 is the most active compound of the testing dataset. This
compound is similar in structure to DB766; it has additional O-Me at the p-positions of the outer
aromatic rings. Both models constructed from experimental inhibitory data at 4°C predict well,
while those for data at 37°C are over predicting significantly. It is also important to note that the
largest deviations in predictions occurred when the experimental values between the two assays
were the greatest. These deviations are seen in the predictions for 10SAB031, 14SMB013, and
DB1868. The residuals between the two biological assays are 0.32, 0.53, and 0.65, respectively.

Molecular descriptor potentials were extrapolated from all four models (Figures 5 and 6).
Figure 5 displays the steric and electrostatic potentials for the models constructed with CoMFA
molecular descriptors and inhibitory data at 4°C and 37°C, respectively. The model with CoMFA
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molecular descriptors and inhibitory data at 4°C show that steric bulk is favored (green) on both
ends of reference compound DB766, as well as above the furan and an isopropyl group. Yet,
disfavored steric potentials (yellow) suggest a size limit to regions near isopropyl substituents.
The electrostatic potentials display the N=C−N groups to exhibit favored (blue) positive charge.
There are very few areas which call for negative charge (red). The model with CoMFA
molecular descriptors and inhibitory data at 37°C display steric potentials similar to those of the
model constructed from the data collected at 4°C. The electrostatic potentials again show
importance of an N=C−N group and suggests more regions where negative charge is favored.

Figure 6 displays the molecular descriptor potentials for the models employing CoMSIA
molecular descriptors. These models displayed smaller more defined regions of importance than
those previously discussed. The model constructed of CoMSIA molecular descriptors and
inhibitory data at 4°C, show similar steric findings to those from the CoMFA models. Steric bulk
is favored at both ends of the compound and there is a size limit to regions of isopropyl
substituents. Electrostatic potentials identify important positive charge regions as those
consisting of isopropyl substituents. Hydrophobic regions are favored (yellow) near the outer
aromatic rings and disfavored (white) by the central furan ring. H-donors are favored (cyan) near
the N=C−N groups, as are H-acceptors (magenta). The model constructed of CoMSIA molecular
descriptors and inhibitory data at 37°C displays similar results to the model with CoMSIA
molecular descriptors and inhibitory data at 4°C. Slight differences in steric potentials were seen
in a shift of positive steric bulk potential from one isopropyl substituent region to the other
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isopropyl substituent. Favored positive electrostatic potentials were reduced and favored
negative electrostatic potentials were increased. A greater amount of favored hydrophobic
potential resulted along the backbone of the reference structure, whereas the amount of
disfavored hydrophobic potential expanded into regions that were previously favored. Favored
H-donor potentials shifted toward the outer aromatic rings, while disfavored potentials were
increased near one of these rings. The favored potentials for H-acceptors surround the N=C−N
groups, whereas disfavored H-acceptor areas are located below the interior aromatic and furan
rings, as well as near one of the isopropyl substituents.

Discussion

Found historically in rural areas of Latin America among those living in close proximity
with vectors and in poor housing conditions, Chagas disease is spread through vectors,
transfusion, organ transplant, and from mother to infant.4,

12

This disease has spread with

migration to the United States and Europe. An estimated 100,000 people in the United States
have this disease which is often unrecognized until the chronic phase is reached. The only
accepted clinical treatments are Nfx and Bz, both of which are not approved for treatment in the
United States. The only way to obtain these compounds is from the CDC, due to their adverse
side effects that can be as devastating as the disease. Hence, the spread of Chagas disease and the
limitations of current therapies necessitate the screening and development of therapeutics that
could replace Nfx and Bz or be used in cases of therapeutic failure. Since several studies have
examined the inhibitory activities of compounds that show inhibitory affinity for targeting T.
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cruzi,13-16, 18-21 this data is readily available and can be employed to develop effective screening
devices and gain insight into the inhibition mechanisms of the compounds.

A pharmacophore was deduced from AIAs with high inhibitory affinities (Figure 1). The
pharmacophore displays the importance of the rigid three ring system through the identification
by hydrophobes. Three acceptor positions of these compounds also appear important; hence, the
atoms surrounding the identified hydrophobes and acceptors of Figure 2 were used for the
alignment of all compounds (Figure 3). PLS was then employed to construct predictive models
that implemented experimental inhibitory data and respective three-dimensional compound
conformations that were defined by the molecular descriptors used, CoMFA or CoMSIA. The
four models developed were all statistically significant and validated accordingly (Tables 1 and 2
and Figure 4). Although all models were shown to be useful predictive devices the models that
are most optimal for predicting inhibitory activity accurately are: (1) the model employing
CoMFA molecular descriptors and experimental inhibitory data acquired at 4°C, and (2) the
model employing CoMSIA molecular descriptors and experimental inhibitory data acquired at
37°C. This appeared to be counterintuitive until models were further examined; the other two
models were much more rigid and this was reflected in predictions. Through the analysis of
model predictions it was found that large deviations in predictions were acquired most often
when the experimental values between the two assays were large.

Molecular descriptor potentials were extrapolated from the models and used to gain
insight about important structural contributions that may be employed to improve compound
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design (Figures 5 and 6). The most useful data appears to be that which comes from the most
optimal models that were previously identified. Steric and electrostatic molecular descriptors for
the model employing CoMFA molecular descriptors and experimental inhibitory data acquired at
4°C displayed that: (1) compounds can be elongated; (2) there is some room for modification of
the isopropyl substituent region of reference compound DB766, although there appear to be
some size limitations; and (3) positive charge is shown to be important to regions of N=C−N
groups (Figure 5). This suggests that the pharmacophore identification of the positive nitrogen
potential, and two donor potentials at the N=C−N groups, have some relevance to important
inhibitory structure for treating blood stored at 4°C (Figure 1). Steric, electrostatic, hydrophobic,
H-donor and H-acceptor molecular descriptors for the model employing CoMSIA molecular
descriptors and experimental inhibitory data acquired at 37°C displayed that: (1) compounds can
be elongated; (2) there is some room for modification of the isopropyl substituent region of
reference compound DB766, although there appear to be some size limitations; (3) the outer
hydrophobic rings appear to be of importance; (4) the addition of H-donors to p-position of the
outer aromatic rings may lead to improved inhibitory compounds; and (5) H-acceptors are
favored at the N=C−N groups of reference structure DB766 (Figure 6).

In summary, a pharmacophore for highly inhibitory compounds was identified, predictive
devices for the screening of inhibitory activity at 4°C and 37°C were constructed for DA and
AIA compounds, and molecular descriptor potentials have been extracted to determine structural
importance as related to the design for novel therapeutics. Structural importance for inhibiting T.
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cruzi was found to be an overall rigid conformation, similar to that of current AIAs, that has
N=C−N groups. Areas for modifications have been identified as the p-position of the outer
aromatic rings, isopropyl substituent regions of reference compound DB766, and central atoms
of the AIAs.
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Tables and Figures

Table 1. Statistics of partial least squares predictive models for a biological dataset of synthetic
diamidines and arylimidamides with activities against Trypanosoma cruzi at 4°C and 37°C.
Models employ either CoMFA or CoMSIA molecular descriptors. The optimal N components
were determined by the smallest predicted error sum of squares; N was determined to be optimal
at 3, 4, 4, and 3 for models displayed from left to right, respectively.
CoMFA
2

Q
SEE
R2
F

CoMSIA

4°C

37°C 4°C

37°C

0.58
0.27
0.94
180

0.56
0.28
0.95
160

0.54
0.26
0.95
260

0.51
0.16
0.98
420
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Table 2. Experimental and predicted pIC50 values for test set compounds. The name of the
structure is displayed to the far left; this is followed by the structure, the experimental pIC 50
values at both 4°C and 37°C, and the predictions from the respective models employing CoMFA
or CoMSIA molecular descriptors at the two temperatures. Diamidines have an overall +2 charge
and arylimidamides have an overall +1 charge.

Experimental
4°C
37°C

CoMFA
4°C 37°C

CoMSIA
4°C 37°C

DB1627

-1.5

-1.5

-1.6

-1.7

-1.6

-1.7

10SAB031

-0.29

-0.61

-0.13

-0.36

0.48

-0.28

DB1362

-0.85

-0.82

-0.66

-1.3

-0.05

-1.1

-1.5

-0.97

-1.3

-1.5

-1.0

-1.3

-1.5

-1.5

-1.1

-2.1

-0.33

-1.4

0.55

1.2

1.2

-1.2

1.3

-1.4

Name

14SMB013

DB613A

DB1868

Structure
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Figure 1. GALAHAD potentials as identified by simulations employing four arylimidamide
compounds (DB1831, DB1853, DB1868 and DB766, Supplemental Table 4, Appendix C) with
high inhibitory affinity. The identified features are color coded: cyan, hydrophobes; magenta,
donor atoms; green, acceptor atoms; red, positive nitrogens.
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Figure 2. Alignment atoms identified on the arylimidamide DB766; these are color coded as in
Figure 1. The atoms representative of the hydrophobes are in cyan and those of the acceptor
atoms are in green.
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Figure 3. The training dataset of 41 compounds (top) was employed to construct partial least
squares regression models, whereas the testing dataset of 6 compounds (bottom) was employed
to assess the models constructed.
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Figure 4. Predictions for the training (blue and green) and testing (red) datasets are displayed
with respect to experimental data. The data from models employing CoMFA molecular
descriptors are on the left, whereas those using CoMSIA molecular descriptors are on the right.
Experimental data for assays and respective predictions at 4°C are displayed above those at
37°C. The trendlines for the training dataset predictions are displayed along with their respective
equations and R2 values.
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37°C

4°C
Steric

Electrostatic

Figure 5. Potentials for models employing CoMFA molecular descriptors and biological pIC 50
values. Favored steric and positive electrostatic potentials are shown in green and blue, whereas
disfavored potentials are displayed in yellow and red, respectively. DB766 is used as a reference
compound; the data displayed are for the overall models. The models for inhibition at 4°C are
displayed to the left of the models for inhibition at 37°C and the steric molecular descriptor
potentials are shown above respective electrostatic potentials.
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4°C
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Hydrophobic

H-Donor

H-Acceptor

Figure 6. Potentials for models employing CoMSIA molecular descriptors and biological pIC50
values. Favored steric, positive electrostatic, hydrophobic, H-donor, and H-acceptor potentials
are shown in green, blue, yellow, cyan, and magenta; negative potentials are displayed in yellow,
red, white, purple, and red, respectively. As in Figure 5, DB766 is used as a reference compound
and the data are displayed for the overall models.
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CHAPTER 5: SETTING ANCHOR IN THE MINOR GROOVE: IN SILICO
INVESTIGATION INTO FORMAMIDO N-METHYLPYRROLE AND NMETHYLIMIDAZOLE POLYAMIDES BOUND BY COGNATE DNA SEQUENCES
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Tricyclic N-Methylpyrrole (Py) and N-methylimidazole (Im) containing polyamide
monocations are known to bind as stacked dimers within the minor groove of DNA and those
with N-terminal formamido (f) substituents bind in a staggered configuration with high
specificity over a range of affinities. Although binding constants have been reported, there is not
a clear understanding of why such constants vary significantly for polyamide dimers and their
respective cognate DNA sequences. By employing computational tools, the following homodimer complexes have been addressed in this study: f-PyPyIm in complex with 5’d(GAACTAGTTC)-3’, f-ImPyPy in complex with 5’-d(GAATGCATTC)-3’ and f-ImPyIm in
complex with 5’-d(GAACGCGTTC)-3’. These complexes were selected based on their 10 to
100-fold differences in binding constants. From this study, it was possible to determine how
polyamides anchor themselves within the minor groove of specific DNA sequences. This is done
through several interactions that provide stability for specific recognition: (1) Py groups secure
themselves between DNA base pairs, (2) lone-pair-Π interactions are formed between DNA
deoxyribose O4’ and Im groups nearest f, (3) minor groove bases hydrogen bond to Im groups
and amides of the polyamide backbone, (4) the f substituents rotate without leaving the minor
groove of DNA and with this rotation form specific hydrogen bonds with electron rich sites on
the floor of the minor groove, and (5) flexible charged N,N-dimethylaminoalkyl substituents
reside favorably in the minor groove of DNA. Results displayed the greatest amount of
interactions and stability for dimer f-ImPyIm in complex with 5’-d(GAACGCGTTC)-3’ and the
least amount in dimer f-PyPyIm in complex with 5’-d(GAACTAGTTC)-3’. Hence, for cognate
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DNA sequences, the relative binding strength of compounds was determined as f-ImPyIm > fImPyPy > f-PyPyIm. This force-field-based computational study is in agreement with
experimental results and provides a molecular rational for the binding constant values.
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Introduction

The antibiotics netropsin and distamycin A, along with synthetic, tricyclic Nmethylpyrrole (Py) and N-methylimidazole (Im) polyamides, bind within the minor groove of
cognate DNA sequences with high specificity but with a surprisingly wide range of affinities
(105 M-1 to 108 M-1).1, 2 The binding sequence specificity of these compounds follows a welldefined set of rules that have been established and confirmed via experimental techniques.1, 3-5
Polyamide compounds align anti-parallel within the minor groove, tail-to-head and head-to-tail,
to form stacked dimers able to recognize specific base pairs: Py overlapped with Py (Py-Py)
recognizes adenine (A) thymine (T) base pairs or TA base pairs, Im overlapped with Im (Im-Im)
recognizes guanine (G) cytosine (C) base pairs or CG base pairs, Im overlapped with Py (Im-Py)
recognizes GC, and Py overlapped with Im (Py-Im) recognizes CG. These relationships are
displayed visually through experimental findings, including X-ray diffraction5-7 and NMR,7, 8 for
complexes of Im- and Py-containing polyamides with duplex oligodeoxyribonucleotides. As a
result of their ability to recognize specific DNA sequences, polyamides are being developed as
potential gene control agents with applications in cancer treatment as well as biotechnology.9-14

Experimental studies have uncovered two structural components of polyamide dimers
that significantly affect DNA binding affinity: the N-terminal formamido group (f) and the
combination and order of the pyrrole and imidazole moieties.1,

2, 6, 8, 15-22

Compared to non-

modified polyamides, those with an N-terminal f substituent displayed increased affinity for
sequence specific binding within the minor groove.1, 2 This general trend can be illustrated with
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results for ImPyPy and f-ImPyPy. The binding affinity of f-ImPyPy (Figure 1) with cognate
DNA increased by approximately 102 M-1 compared to ImPyPy with cognate DNA when a
terminal f was present. The association and dissociation rates were slower for the f derivative and
the polyamide stacking mode for the complex with f compounds were staggered while the others
were overlapped.2 Similar results have also been observed for other non-modified and f modified
polyamides with their respective cognate DNA sequences.1, 2

In silico docking and molecular dynamics studies have also provided valuable insight into
DNA-polyamide, and other compound, interactions.23-27 For example, the flexible β-Dp tails of
the ImHpPyPy-β-Dp polyamides contributed to binding through water mediated contact with
phosphate oxygen.28 Docking studies have also aided in the construction of DNA-polyamide
complexes to examine the movements and interactions of individual bases, such as the roll of
base pairs when computationally constructed polyamides were examined in complex with
DNA.24, 29 Experimental thermodynamic data have been examined through limited docking of fImPyIm (Figure 1) polyamides.17

The unanswered fundamental question in the experimental studies is why the
combination and arrangement of Py and Im moieties have such a significantly different effect on
binding affinity with cognate DNAs.1,

18

Given these observed differences, analyzing

experimental binding constants with regard to molecular structure interactions of DNApolyamide complexes can provide valuable insight. The goal of this study is to use in-depth
docking methods to compare and examine how polyamides interact with DNA structure and
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groups in the minor groove. Through the use of computational tools, several complexes were
examined: f-PyPyIm in complex with cognate sequence 5’-d(GAACTAGTTC)-3’, f-ImPyPy in
complex with cognate sequence 5’-d(GAATGCATTC)-3’, and f-ImPyIm in complex with
cognate sequence 5’-d(GAACGCGTTC)-3’. These complexes have experimentally determined
binding constants of 1 × 106, 1 × 107, and 2 × 108 M-1, respectively.1, 18 This study represents the
first in-depth docking approach to examine these polyamides and their cognate sequences to
address the experimental affinity variations. Significant differences were found between the
strongest and weakest binding polyamide dimers.

Experimental Procedures

Polyamides f-PyPyIm, f-ImPyPy, and f-ImPyIm were previously synthesized and
examined in complex with 5’-d(GAACTAGTTC)-3’, 5’-d(GAATGCATTC)-3’, and 5’d(GAACGCGTTC)-3’, respectively. Surface plasmon resonance (SPR) was employed to
determine binding constants.1, 18

Docking Preparation. The three polyamide-DNA complexes were evaluated by
employing SYBYL 8.130 software on a Fedora Core 5 Linux Workstation. Solution nuclear
magnetic resonance (NMR) structure 1B0S31 was obtained from the protein data bank; this
structure was used as a template and as a reference complex. 1B0S, an f-ImImIm dimer in
complex with 5’-d(GAACCGGTTC)-3’, was mutated using the Biopolymer and Building and
Editing modules in SYBYL to form: the f-PyPyIm dimer in complex with 5’-
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d(GAACTAGTTC)-3’, the f-ImPyPy dimer in complex with 5’-d(GAATGCATTC)-3’, and the
f-ImPyIm dimer in complex with 5’-d(GAACGCGTTC)-3’. These modified complexes were
then minimized for 100 iterations using the Tripos force field; thus, allowing the somewhat rigid
DNA to accommodate the mutated bases and polyamides through slight changes to the width of
the minor groove. Polyamide dimers were then moved to second memory locations, separate
molecular areas within the SYBYL graphical user interface. The ability to move, or rather
extract, the compounds into a separate molecular area allowed the compounds to explore
torsional angles, translation, and rotational angles independent of the DNA when the FlexiDock
genetic algorithm was employed. The two compounds of the dimer were given torsional,
translational, and rotational freedom independent of each other; yet, they were docked
simultaneously into the DNA. The structures of the polyamides are displayed in Figure 1.

The FlexiDock module of the SYBYL software suite was then implemented. Ten
different random starting locations were assigned and employed by the genetic algorithm one at a
time for a total of ten docking trials. Calculated and assigned as in previous studies, the large
amount of generations ensured that lowest energy conformations were obtained.32,

33

Each

docking trial consisted of 516 000 generations. The dimers and the DNA were permitted
torsional, rotational, and translational flexibility throughout the docking process. Atomic charges
for the DNA were calculated using the Kollman All-Atom protocol, while the dimer was
assigned Gasteiger-Huckel charges. All possible hydrogen bonding sites on the dimer and
cognate DNA were targeted for function where possible. From each docking the 20 lowest
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energy structures were selected. Hence, 200 structures were produced for each complex
examined; 10 random starting locations × 20 low energy structures from each docking. The
energy values (EMM) for the overall lowest energy complexes are displayed in Table 1.

Docked Structure Analyses. Interactions were calculated and viewed using modules and
tools of the SYBYL software package. The FlexiDock module optimizes torsional angles,
translation, and rotational angles to minimize the energy function. Compounds were examined
using the FlexiDock scoring function, which is based on the Tripos force field and estimates the
energy for the dimer, the receptor, and the complex. The score is evaluated with van der Waals,
electrostatic, torsional, and hydrogen bonding energies; lower energy in the complex state
suggests better binding. Hydrogen bond distances were analyzed using the “Display H-Bonds”
and “Measure” options. Values obtained were averaged for the 20 lowest energy conformations
of each complex. All measurements were from heavy atom to heavy atom. The 40 lowest energy
complex conformations displayed variations of the f group. The Advanced Computation and
Dock modules, of the SYBYL software suite, were employed to gain further explanation into the
Im and Py similarities and differences with respect to electrostatics and dipoles.

Grid Search, an application of the Advanced Computation module, was used to examine
the f groups, of the lowest energy conformation of each complex, in Cartesian space through
systematic rotation about bonds using defined increments of 20ᴼ for a total of 360ᴼ. At each
increment the torsional bond angle was constrained and the conformation was minimized. The
minimization of complexes employed default parameters.30 This allowed for a systematic
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exploration of torsional freedoms with regard to respective energies. These complexes were then
arranged by f group rotation in increments of 20ᴼ and then averaged so that the general trend of
the energies could be viewed, analyzed, and compared effectively.

The Dock module of SYBYL 7.334 was then employed to re-examine structures and
calculate energy values for low energy complexes obtained via FlexiDock and Grid Search. This
software was ideal since structures could be observed and energy values could be calculated
without changes to DNA-polyamide complex conformations.

Accessible solvent area (ASA) was examined for each lowest energy complex with
Chimera software.35 The module employed was the Area/Volume from Web (StrucTools server)
with calculation options Gerstein ASA, surface probe 1.4 and all atoms except water. ASA was
acquired for each complex, DNA, and individual polyamide. The ASA was summed for each
atom of each residue and polyamide.

The Spartan ’0436 software package was employed to examine geometry optimized Py
and Im groups using a single point ab initio calculation employing the Hartree-Fock 6-31G**
level. This allowed for comparisons of ab initio calculated electrostatic potential maps and
dipoles.
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Results

The modification of NMR solution structure 1B0S resulted in the construction of the fPyPyIm dimer in complex with 5’-d(GAACTAGTTC)-3’, the f-ImPyPy dimer in complex with
5’-d(GAATGCATTC)-3’, and the f-ImPyIm dimer in complex with 5’-d(GAACGCGTTC)-3’.
Each of the polyamides underwent extensive docking, as did reference polyamides from 1B0S,
within their respective DNAs to yield optimized structures.

Reference complex, 1B0S, displayed only slight deviations from the refined average
structure obtained via solution NMR. The calculated root mean squared error between the NMR
structure and the lowest energy docked structure was approximately 0.60. Figure 2 displays the
alignment of the 10 lowest energy 1B0S-docked reference structures.

f-PyPyIm in complex with 5’-d(GAACTAGTTC)-3’. The low energy structures of fPyPyIm are hydrogen bonded as a staggered dimer to 5’-d(GAACTAGTTC)-3’ (Figure 3). The
base pairs involved in hydrogen bonding include those within the center of the DNA, 5’d(ACTAGT)-3’, the AT base pair followed by CG, TA, AT, GC, and TA, respectively. Each
image of Figure 2 (Right) was taken as the DNA was rotated to the right, so that the bases would
take on a view that was as linear as possible.

The hydrogen bond displayed in the top AT base pair is between the upper dimer
compound amide NH of the charged polyamide tail and the C2 O of the T base. Both of the
hydrogen bonds displayed in the following image of CG also exist between the upper compound
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of the dimer and the G base subsequent to the T on the same DNA chain. The hydrogen bonds
are between the Im N and the G C2 NH2 and between the following amide NH and the G N3.
Because of the staggered stacking, the TA base pair represents the first image in which
heterocycles from both compounds of the dimer are present and both are hydrogen bonding. In
this image the upper dimer compound amide NH following the Py is forming a hydrogen bond
with the A N3, while the lower compound of the dimer is forming a hydrogen bond between the
amide NH above the Py and the T C2 O. The image of AT and the dimer compounds also
displays both compounds forming hydrogen bonds to respective DNA bases. The upper
compound amide NH is hydrogen bonded to the T C2 O, while the lower compound amide NH is
hydrogen bonded to the A N3. The following image displays base pair GC which hydrogen
bonds with the lower dimer compound. The amide NH prior to the Im is hydrogen bonded to G
N3 and the Im N is hydrogen bonded to the G C2 NH2. The TA base pair, of the last image, is
similar to the first base pair AT. In this region the NH following the Im of the lower dimer
compound hydrogen bonds to the T C2 O.

f-ImPyPy in complex with 5’-d(GAATGCATTC)-3’. Docking results display f-ImPyPy to
be hydrogen bonded more favorably to 5’-d(GAATGCATTC)-3’ (Figure 4) than the f-PyPyIm
dimer described above. Further stabilization is obtained from lone-pair-Π interactions between
DNA deoxyribose O4’ and the Im groups of the dimer polyamides. Similar to the compounds
observed in Figure 3, f-ImPyPy is bound in a staggered dimer conformation and the base pairs
involved in hydrogen bonding include those within the center of the DNA, in this case 5’-
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d(ATGCAT)-3’. The images of Figure 4 (Right) show the AT base pair followed by TA, GC,
CG, AT, and TA.

The hydrogen bonds displayed in the top AT base pair region are between the upper
compound amide NH of the charged polyamide tail and the C2 O of the T base and between the
upper compound amide NH and the lower compound f O. The hydrogen bond displayed in the
following image of TA exists between the upper compound amide NH subsequent to the Py and
the A N3. The GC base pair represents the first image in which both compounds of the dimer are
visible and both are partaking in hydrogen bonding. In this image the upper dimer compound
amide NH following the Py is forming a hydrogen bond with the C C2 O, while the lower
compound of the dimer is forming hydrogen bonds between the f amide NH and the G N3 and
the Im N and the G C2 NH2. The image of CG and the dimer compounds also displays both
compounds forming hydrogen bonds to respective DNA bases. The upper compound Im N is
hydrogen bonded to the G C2 NH2 and the following amide NH is hydrogen bonded to the G N3.
The lower compound amide NH is hydrogen bonded to the C C2 O. The following image
displays base pair AT. Hydrogen bonds displayed in this base pair region exist between the
compounds of the dimer and between the lower compound amide NH, above the Py, and the A
N3. The last image, of the TA base pair, displays a single hydrogen bond between an amide NH
and the T C2 O.

f-ImPyIm in complex with 5’-d(GAACGCGTTC)-3’. Docking results display the fImPyIm dimer to be hydrogen bonded to 5’-d(GAACGCGTTC)-3’ (Figure 5) even more
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favorably than either of the previous dimers to their cognate sequences. Similar to what was seen
in Figure 4, Figure 5 shows stabilization in lone-pair-Π interactions between DNA deoxyribose
O4’ and the Im group nearest the f of the polyamides. As seen in Figures 3 and 4, these
compounds take on a staggered dimer conformation and the base pairs involved in hydrogen
bonding include those within the center of the DNA, in this case 5’-d(ATGCAT)-3’. As
displayed in Figure 3 and 4, the images of Figure 5 (Right) show the AT base pair followed by
TA, CG, GC, CG, GC, and TA.

The hydrogen bond displayed in the top AT base pair region is between the upper
compound polyamide charged tail amide NH and the C2 O of the T base. Four hydrogen bonds
exist in the following image of CG. These hydrogen bonds are between the upper compound
amide NH and lower compound f O, between the upper compound Im and the G C2 NH2,
between the amide NH subsequent to the Im of the upper compound to the G N3 and between the
f O of the lower compound and the G C2 NH2. The GC base pair represents the first image in
which both compounds of the dimer are present and both are partaking in hydrogen bonding to
both strands of the DNA. In this image the upper dimer compound amide NH following the Py is
forming a hydrogen bond with the C C2 O, while the lower compound of the dimer is forming
hydrogen bonds between the amide NH and the G N3 and the Im N and the G C2 NH2. The
image of CG and the dimer compounds also displays both compounds forming hydrogen bonds
to respective DNA bases. The upper compound Im N is hydrogen bonded to the G C2 NH2 and
the following amide NH is hydrogen bonded to the G N3. The lower compound amide NH is
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hydrogen bonded to the C C2 O. The following image displays base pair GC. Similar to the first
CG region, four hydrogen bonds are displayed in this base pair region. These hydrogen bonds are
between the upper compound f O and lower compound amide NH, between the lower compound
Im N and the G C2 NH2, between the amide NH prior to the Im of the upper compound to the G
N3 and between the f O of the upper compound and the G C2 NH2. The last image, of the TA
base pair, displays a single hydrogen bond between an amide NH and the T C2 O.

Terminal Interactions. Overall docking results for all three complexes display significant
flexibility in the polyamide charged tails, as expected, and significant rotation of the f
substituent, which provides unexpected extra insights, while the heterocycles and amide groups
exhibit less flexibility. As noted above, the charged tail amide NH forms hydrogen bonds to T
C2 O base pairs (Figures 3, 4, and 5). The remainder of each polyamide charged tail resides
favorably within respective cognate DNA minor grooves. Rotation of the f group allows for
different hydrogen bonds to form and stabilize the complex. Figure 6 displays such changes
within overlaid lowest energy structures of f-ImPyIm in complex with 5’-d(GAACGCGTTC)-3’.
The lowest energy structure, previously addressed in Figure 5, is shown as caped sticks, while a
second low energy conformation is displayed as ball and stick structures. The f NH of the most
common lowest energy structures obtained from docking displays hydrogen bonds to G N3 of
the first GC base pair of the recognition sequence (Figures 5 and 6, Upper Right); however, upon
rotation of f this interaction is lost and new hydrogen bonds are formed between the f O and the
G C2 NH2 of the first CG base pair and the G C2 NH2 of the first GC base pair (Figure 6, Lower
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Right). When this rotation occurs the hydrogen bond between the dimer polyamides, f O and
charged tail NH, can no longer form. The rotation of f can occur at either end of the dimer
formation. These formations, obtained via FlexiDock, were analyzed further through Grid
Search. Figure 7 displays the energy fluctuations as rotation occurs in the f group. In the plot, the
lowest energy complex conformations, with respect to f torsional angles, are for the two
hydrogen bonded conformations in Figure 6.

Complex Energies. Relative total energies for lowest energy complexes subsequent to
FlexiDock and Grid Search, calculated via Dock, are reported in Table 2. Total energies are the
sum of steric and electrostatic energies. For complexes from FlexiDock, the steric and
electrostatic energies are respectively, -23.5 and -56.6 kcal/mol for the complex with dimer fPyPyIm; -73.9 and -44.9 kcal/mol for the complex with f-ImPyPy; and -77.9 and -52.4 kcal/mol
for the complex with dimer f-ImPyIm. For each complex acquired via Grid Search the steric and
electrostatic energies are respectively, -75.3 and -28.0 kcal/mol for the complex with dimer fPyPyIm, -75.3 and -42.6 kcal/mol for the complex with f-ImPyPy, and -72.7 and -53.3 kcal/mol
for the complex with dimer f-ImPyIm. Since the 180° rotation of f occurred in the top twenty
percent of lowest energy complexes, as viewed in Figure 6, energies for these complexes were
also calculated subsequent to Grid Search (Table 2). For each complex acquired steric and
electrostatic energies are respectively, -72.6 and -26.8 kcal/mol for the complex with dimer fPyPyIm, -72.4 and -44.8 kcal/mol for the complex with f-ImPyPy, and -73.6 and -52.6 kcal/mol
for the complex with dimer f-ImPyIm.
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Accessible Surface Area (ASA). Buried surface on complex formation was addressed
through ASA calculations. Figure 8 displays the surfaces for the complexes, DNA and
polyamides; blue surfaces encompass positively charged regions, while red cover those that are
negatively charged. Positive and negative regions of the polyamides can align with those of the
DNA minor groove to maximize electrostatic interactions. This was further supported with the
ASA values for the complexes, DNA and polyamide (Figure 9). The red area represents the
DNA. Notice that the DNA ASA is fairly similar for all three complexes, as are the three
polyamide areas displayed in green. The blue areas show differences related to the respective
DNAs binding their specific polyamides for complex formation: (1) the complex with f-PyPyIm
displays more ASA at the T bases of the recognition sequence than the other two complexes, (2)
the complex with f-ImPyPy displays a decreased ASA near the A bases of the recognition
sequence, and (3) the complex with f-ImPyIm is the most uniform and consists of the most
buried ASA.

Ab Initio Electrostatic Potential Maps. To understand the energy contributions from
polyamide structures, it is informative to compare the ab initio calculated electrostatic potential
maps for the Py, Im, and amide units of the polyamide dimers (Figure 10) with each other as well
as with the low energy stacked complexes shown in Figure 11. Although the dipole moments of
the Py and Im heterocycles point in the same direction, the magnitude of the dipole is larger for
the Im and the electrostatic potential maps clearly show a significantly different distribution of
molecular electrostatic potential. With both the Py and Im the positive potential is distributed on
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the N-Me group and close vicinity. With the Py the highest negative potential is on the Py Πsystem while in the Im, it is on the unprotonated Im-N (Figure 10). As expected, the negative
potential on the amide is highest on the carbonyl O while the positive potential is on the -NH.
With this distribution, the dipole moment of the amide points in the opposite direction to the
heterocycles (Figure 10) in the orientation of DNA binding (Figure 11).

Each of the stacked polyamides has six heterocycles that can be evaluated in terms of the
maps in Figure 10. Starting with the weakest binder, f-PyPyIm (Figure 11), the heterocycles
interact as follows: At top of the Figure, (1) the first Im is relatively unstacked; (2) the next
heterocycle (lower molecule of the dimer) is stacked favorably with a positive amide -NH over
the negative area of the pyrrole; (3) the next two pyrroles are stacked such that their positive
regions are near negative carbonyl O atoms, a fairly favorable orientation; (4) The next Py has its
most positive region closely stacked with a positive -NH, an unfavorable interaction; and (5) the
last Im is not well stacked. In the strongest binding f-ImPyIm complex (Figure 11), (1) the first
Im is not strongly stacked; (2) the next Im (lower molecule) is favorably stacked with an amide
with the negative carbonyl O of the amide near the most positive region of the Im (Figure 10)
and the amide positive H of the -NH stacked near the negative Im-N; (3) the next two Py groups
are also favorable stacked with amide negative O atoms near their positive N-Me groups; (4) the
next Im is in a similar favorable orientation with an amide O near the positive N-Me of the
imidazole while the positive H of the amide -NH is near the Im negative N; and (5) the last Im is
not as strongly stacked as the internal heterocycles. It should be noted, however, that the terminal
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two Im groups are stacked with their most negative regions near the most positive regions of the
adjacent Ims and, given the larger dipole moment of the Im versus Py groups (Figure 10), this
should be a favorable contribution. In summary, the electrostatic interactions between the
stacked heterocycles appear to make favorable contributions to dimer binding of both f-PyPyIm
and f-ImPyIm but there are more and stronger favorable interactions in the f-ImPyIm dimer.

Discussion

Experimental results for simple tricyclic polyamides, such as those in Figure 1, have a
puzzling, large variation in energies when bound by their cognate DNA sequences. 1, 2 We have
conducted a docking study for the polyamides of Figure 1 and respective cognate DNA to
provide some initial molecular level information on the different complexes. Three components
that contribute to polyamide dimer-DNA interactions were investigated in the docked structures:
(1) hydrogen bonding, (2) buried surface on complex formation, and (3) electrostatic interactions
of the polyamide units in the stacked dimer. All of these interactions have been evaluated and
these results provide insight into the large variations in binding constants.

When analyzing the dimer of f-PyPyIm in complex with 5’-d(GAACTAGTTC)-3’ and its
resulting position due to interactions with the minor groove, it is important that the dimer overlap
is a staggered conformation of central Py-Py/Py-Py (Figures 3 and 11). The stacked Py groups
form a stable motif with the ability to anchor these polyamides into stable dimer conformations
in the minor groove (Figures 2). Figure 12 illustrates the models from Figure 3 in two-
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dimensions and shows the interactions of the Py-Py stacked motif with the central base pairs of
the cognate binding sequence. The Py groups fit between the bases and aid in position indexing
so that amide NH groups and the Im N can form favorable hydrogen bonds with base functional
groups. The electrostatic potentials also play a significant role in both the specific interactions
and complex stabilization (Figures 8 and 9).

The f-ImPyPy dimer polyamides also overlap in a staggered conformation of Py-Im/ImPy (Figures 4 and 11). As in Figure 3, steric interactions of the stacked Py groups appear to play
an important role in anchoring these polyamides within their recognition sequence. Py groups
index themselves with steric complementary between the base pairs. The Im groups form
favorable hydrogen bonds, due in part to the added stability provided by the steric positioning
interactions of the Py groups. The optimum positioning of the Py and Im groups allows the dimer
to form hydrogen bonds between the ends of the upper and lower stacked compounds in Figures
4 and 13. Polyamide f-ImPyPy, in complex with 5’-d(GAATGCATTC)-3’, displays stacking
differences that vary from those of f-PyPyIm in complex with 5’-d(GAACTAGTTC)-3’ and
these appear to be due to electrostatic interactions between the polyamides and the DNA (Figures
8, 10, and 11). DNA and polyamides were mobile throughout the docking process; the f-ImPyPy
polyamides moved into minor groove regions that are more optimal than those of the f-PyPyIm
complex (Figures 4 and 13). This allows for more favorable interactions and a larger negative
calculated energy, EMM (Table 2).
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Similar to f-PyPyIm and f-ImPyPy dimers, f-ImPyIm polyamide dimers overlap in their
minor groove location in a staggered conformation of Py-Im/Im-Py (Figures 5 and 14). As seen
in Figures 3 and 4, the Py groups index themselves between base pairs with steric
complementary and play an important role in anchoring the compound into stable low energy
docked conformations with the best possible positioning. The Im groups contribute to the GC
base pair recognition and general affinity. The optimum positioning of the Py and Im groups also
allows the dimer to form hydrogen bonds between the charged N,N-dimethylaminoalkyl tail NH
of the upper compound and the f O of the lower compounds. The Im groups on the ends also
contribute significantly to the amount of hydrogen bonding. This is by far the most stable of the
three structures evaluated, as shown by the wealth of hydrogen bonding and the positioning of
the compounds. The terminal Im, not involved in the Py-Im/Im-Py stacking, forms tight
hydrogen bonds and the compounds are pulled in close to the DNA. These interactions are
enhanced by favorable electrostatic interactions that reduce the ASA (Figures 8 and 9). The
DNA and compounds form tight favorable interactions and the EMM value for the complex with
f-ImPyIm is more negative than the values obtained for complexes with compounds f-PyPyIm or
f-ImPyPy.

Given that the compounds of the dimer are binding to the same sequences on opposite
DNA strands one may expect the hydrogen bonds to be quite similar. The small differences in
observations of individual structures are as expected for flexible docking. The complex with fPyPyIm does not exhibit hydrogen bonding between the two compounds of the dimer and these
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compounds exhibit more mobility within the DNA minor groove (Figures 3 and 12). The
hydrogen bond length similarities in compound binding to respective DNA strand are only found
in two locations, at the terminal T and the center A of recognition sequence 5’-d(ACTAGT)-3’.
The complex with f-ImPyPy exhibits hydrogen bonding within the dimer, at both ends of the
compounds, and this results in a greater amount of consistent hydrogen bond length similarities
between compounds and their respective DNA strands (Figures 4 and 12). The hydrogen bond
length similarities in compound binding to respective DNA strand are found in three locations
central the recognition site, at the G, C, and A of recognition sequence 5’-d(ATGCAT)-3’. The
complex with f-ImPyIm exhibits hydrogen bonding within the dimer and to the bases of the
parallel DNA strand (Figures 5 and 14). The hydrogen bond length similarities in compound
binding to respective DNA strands are found throughout the recognition site, at the G, C, G, and
T of recognition sequence 5’-d(ACGCGT)-3’.

The terminal groups of the polyamides are flanked by a flexible charged tail and a small f
substituent. The movements of the charged N,N-dimethylaminoalkyl tail were minor in
comparison to a previous molecular dynamics study examining polyamides with longer tails. 28
The charged N resided toward the center of the minor groove between the phosphates of the
DNA backbone. Perhaps, possible interactions with phosphates are limited by the size of the tail
and the stable hydrogen bonding of the tail NH with T C2 O.

The rotation of the f group in the stacked complexes is a significant observation in these
experiments. The terminal f substituents are small enough to rotate in the dimer widened minor
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groove without the polyamide leaving the minor groove and energies obtained suggest that the
two orientations shown in Figure 6 contribute to binding (Figures 6, 7, and Table 2). The steric
contributions to energy are similar, most likely due to the similar size of all three polyamides and
the areas occupied; electrostatics differ much more. It is also important to note that stability of
structures resulted in consistency of EMM values, even when f rotated 180ᴼ. These results suggest
that when a single polyamide begins to deviate from its recognition site, a rotation of f occurs
and new bonds are formed; thus, keeping the complex longer than if the f substituent was absent.
This discovery explains our recent observations that modifications of the f group with other acyl
groups results in diminished binding affinity.22 Specifically, the order of binding constants was fImPyIm >> Acetyl-ImPyIm > N-methylureidoacetyl-ImPyIm > trifluoroacetyl-ImPyIm. This is
consistent with the suggestion that small and planar N-terminus subsitituents promote favorable
binding with DNA. Furthermore, consistent with the role of the f or acyl group, ImPyIm analogs
bearing an NH2 at the N-terminus and non-formamido-ImPyIm gave the weakest binding
indicating the importance of having an f group to form favorable hydrogen bonds with sites on
the floor in the minor groove.

Previously, experimental studies employing surface plasmon resonance (SPR) acquired
binding constants for f-PyPyIm in complex with 5’-d(GAACTAGTTC)-3’, f-ImPyPy in complex
with 5’-d(GAATGCATTC)-3’, and f-ImPyIm in complex with 5’-d(GAACGCGTTC)-3’; these
constants are approximately 1 × 106, 1 × 107, and 2 × 108 M-1, respectively.1, 18 In our studies,
EMM values were calculated for the lowest energy complexes obtained via FlexiDock and Grid
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Search (Table 2); the more negative the value, the stronger the binding. Both the experimental
and the in silico data are in agreement. The ranked binding from strongest to weakest is: fImPyIm in complex with 5’-d(GAACGCGTTC)-3’ > f-ImPyPy in complex with 5’d(GAATGCATTC)-3’ > f-PyPyIm in complex with 5’-d(GAACTAGTTC)-3’.

This in-depth docking approach provides useful new molecular information about
polyamide complexes and how they are anchored within the minor groove. Hydrogen bonding,
steric and electrostatic interactions all play a role, along with compound conformation, to
determine how a compound will recognize specific DNA sequences. Specifically, f-ImPyIm
binds better than the other dimers as a result of the greater amount of intra-dimer and intracomplex hydrogen bonds, lone-pair-Π interactions, optimum dipole interactions, as well as
excellent steric fit and electrostatic interactions. We are currently employing these findings to
improve compound design. Findings suggest that dimer spacing provided by Py groups and
hydrogen bonding interactions of Im groups can be employed to recognize even longer DNA
sequences. This of course is given that recognition compounds: (1) keep a curvature that
parallels that of DNA, (2) stack efficiently maintaining electrostatic interactions, and (3) have the
ability to form hydrogen bonds on both ends. Insights from this study suggest that compounds
such as f-ImPyImPyIm should bind and recognize 5’-d(-ACGCGCGT-)-3 with similar affinity
and greater specificity than f-ImPyIm binds and recognizes 5’-d(GAACGCGTTC)-3’. These
studies are in progress and the results will be reported in due course.
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Tables and Figures

Table 1. Energies (EMM) gained from FlexiDock docking studies. These values are in kcal/mol.
EMM
f-PyPyIm with 5’-d(ACTAGT)-3’

-594

f-ImPyPy with 5’-d(ATGCAT)-3’

-670

f-ImPyIm with 5’-d(ACGCGT)-3'

-765
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Table 2. Total energies, reported as EMM values, gained from Dock for the lowest energy
complexes obtained via FlexiDock and Grid Search. The EMM values for both low-energy
structures acquired via Grid Search are labeled 1 and 2, respectively. Grid Search 1 relates to the
structures with the f positioned as in the top right image of Figure 6, while Grid Search 2 relates
to the structures with the f positioned as in the bottom right image of Figure 6. All EMM values
are in kcal/mol.
FlexiDock

Grid Search 1

Grid Search 2

f-PyPyIm with 5’-d(ACTAGT)-3’

-80.1

-103

-99.4

f-ImPyPy with 5’-d(ATGCAT)-3’

-119

-118

-117

f-ImPyIm with 5’-d(ACGCGT)-3'

-130

-126

-126
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f-PyPyIm

f-ImPyPy

f-ImPyIm

Figure 1. Two-dimensional illustration of polyamide structures (Left) with abbreviations (Right):
formamido (f), N-methylpyrrole (Py) and N-methylimidazole (Im). Dimer complexes of these
compounds are shown docked into cognate DNA sequences in Figures 3-5.
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Figure 2. Overlay of the 10 lowest energy structures for the docking of reference structure, 1B0S,
polyamides into cognate DNA. The refined average structure obtained from the protein data bank
is displayed in green, while all other low energy complexes are displayed by atom type.
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Figure 3. f-PyPyIm in complex with 5’-d(GAACTAGTTC)-3’. For clarity, the terminal bases are
not displayed in the images and the images are of only the lowest energy conformation. The
image on the left displays the complex as a whole, while the segmented images on the right show
the individual bases as the polyamide-DNA complex is rotated to the right. Magenta arrows are
displayed on the left image; these point to the Py groups. On the right, the bases are labeled in
green, the hydrogen bonds are in white and the average respective hydrogen bond lengths are in
yellow. Notice that the Py groups index themselves with steric complementary between base
pairs, this is pointed out on the left and more clearly viewed in the central TA and AT images on
the right.
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Figure 4. f-ImPyPy in complex with 5’-d(GAATGCATTC)-3’. For clarity, the terminal bases are
not displayed in the images and the images are of only the lowest energy conformation. The
image on the left displays the complex as a whole and identified lone-pair-Π interactions
(orange), while the segmented images on the right show the individual bases as the polyamideDNA complex is rotated to the right (labeled as in Figure 3).
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Figure 5. f-ImPyIm in complex with 5’-d(GAACGCGTTC)-3’. For clarity, the terminal bases
are not displayed in the images and the images are of only the lowest energy conformation. The
image on the left displays the complex as a whole, while the segmented images on the right show
the individual bases as the polyamide-DNA complex is rotated to the right (labeled as in Figures
3 and 4).

155

2.6 Å

2.6 Å
3.2 Å

Figure 6. f-ImPyIm in complex with cognate sequence 5’-d(GAACGCGTTC)-3’. The image on
the left displays the overlap of the two low energy dimer conformations in the minor groove of
the lowest energy DNA base pairs affected by f rotation. In an enlarged view for clarity, the
images on the right display the two low energy conformations individually. These conformations
consist of different hydrogen bonding interactions, which are shown in green. The upper right
image displays the f N hydrogen bonding to the G N3 of the first GC base pair of the recognition
sequence; whereas the lower right image displays the hydrogen bonding of f O to the G C2 NH2
of the first CG base pair, as well as the G C2 NH2 of the first GC base pair.
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Figure 7. Polyamide structure (Left) with an arrow pointing to the bond rotated via Grid Search.
X represents N-methylpyrrole (Py) and/or N-methylimidazole (Im) depending on the complex
employed for formamido (f) bond rotation. The graph (Right) displays the averaged, normalized
energy values for each structure obtained after a 20ᴼ rotation of one or both f bonds within the
dimer. Data for complexes with f-PyPyIm, f-ImPyPy, and f-ImPyIm, are displayed in blue, red
and green, respectively. The lowest energy conformations are at 0ᴼ and 180ᴼ. At 0ᴼ the f is
positioned as in Figure 6, Upper Right, and position 180ᴼ is shown in Figure 6, Lower Right.
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f-PyPyIm

f-ImPyPy

f-ImPyIm

Figure 8. Surfaces displaying electrostatic potentials with respect to coulombic coloring for the
complexes (Left), DNA (Center) and polyamides (Right); blue surfaces encompass positively
charged regions, while red cover those that are negatively charged.
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Base Pairs and Polyamides
Figure 9. Accessible Surface Area (ASA) calculated for each base pair and polyamide in
complex (blue) and alone (red for DNA and green for single polyamide). The ASA is reported in
Å2 and the DNA bases are denoted as dA, dT, dG and dC for adenine, thymine, guanine and
cytosine, respectively. Orange and purple lines spanning the three ASA graphs separate the two
DNA strands and the polyamides. Both DNA strands are shown from 5’ to 3’, displaying the
differences in each strand with (blue) and without (red) compound interaction. Yellow boxes
highlight the specific recognition sites for each complex. The polyamides are displayed as L1
and L2. When analyzing only a single polyamide (green), this compound is L1.
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N-Me-Py
D = 2.1 Debye

diMe-Amide
D = 3.9 Debye

N-Me-Im
D = 4.4 Debye

Figure 10. Ab initio calculated electrostatic potential maps for the Py, Im and amide units of the
polyamide dimers, respectively these units are shown on the left with their dipole moments. The
electrostatic potentials are shown in the center, blue is positive and red is negative, and the
magnitudes of the dipoles are displayed on the right.

160

+

+
+

+
+

+

Figure 11. Top view of dimers formed during docking (Left) and schematic representation
(Right) with Py in gray and Im in white. The DNA has been removed so that preferred staggered
conformations can be viewed. From top to bottom, the dimers come from f-PyPyIm in complex
with 5’-d(GAACTAGTTC)-3’, f-ImPyPy in complex with 5’-d(GAATGCATTC)-3’ and fImPyIm in complex with 5’-d(GAACGCGTTC)-3’. Notice the spacing of the dimers.
161

f-PyPyIm/5’-d(GAACTAGTTC)-3’

+
3.0 Å
2.8 Å
3.0 Å
3.0 Å

3.5 Å
3.5 Å

2.7 Å
3.2 Å
3.2 Å
3.0 Å
+

Figure 12. Two-dimensional illustration of f-PyPyIm in complex with cognate sequence 5’d(GAACTAGTTC)-3’. Hydrogen bonds are displayed by dashed lined with respective distances.
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Figure 13. Two-dimensional illustration of f-ImPyPy in complex with cognate sequence 5’d(GAATGCATTC)-3’. Hydrogen bonds are displayed by dashed lined with respective distances.

163

f-ImPyIm/5’-d(GAACGCGTTC)-3’

+
3.0 Å
3.0 Å

2.6 Å

3.0 Å
2.9 Å
2.6 Å

2.5 Å
3.6 Å

3.7 Å

2.4 Å

3.0 Å

2.8 Å

2.8 Å
2.5 Å

2.5 Å
3.0 Å
+

Figure 14. Two-dimensional illustration of f-ImPyIm in complex with cognate sequence 5’d(GAACGCGTTC)-3’. Hydrogen bonds are displayed by dashed lined with respective distances.
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Appendix A

Supplemental Table 1. Compounds employed for training and testing.
Scaffold

Compound

Ki of P2 (µM)

(G0)
(kJ/mol)

Source

A

1-deazaadenosine

45.4

-24.8

(1)

A

1-deazapurine

131

-22.2

A

2,6-diaminopurine-2'-d-riboside

4.44

-30.6

A

2-chloro-adenosine

9.65

-28.6

Aldrich
MP
Biomedicals
TriLink
Biotech

7.5

-29.3

(10)

A

A

2'-deoxyadenosine

0.23

-37.9

Sigma

A

2'-deoxyinosine

165

-21.6

Sigma

A

2-hydroxy-6-aminopurine

9.7

-28.6

Acros

A

2-nitoradenosine

81

-23.4

(1)

A

3-deaza-adenosine

0.29

-37.3

Sigma

-27.5

TriLink
Biotech

A

6-chloropurine riboside

15.4
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Supplemental Table 1 (continued)
Scaffold

Compound

Ki of P2 (µM)

(G0)
(kJ/mol)

Source

A

8-azidoadenosine

331

-19.9

(8)

A

8-bromoadenosine

37.8

-25.2

Acros

A

9-deazaadenosine

12.2

-28

(7)

A

adenine

0.3

-37.2

Sigma

A

adenosine

0.92

-34.5

Sigma

A

allopurinol

255

-20.5

Sigma

A

DAPI

0.47

-36.1

Fluka

A

DB1208

0.37

-36.7

(5)

A

DB1464

0.15

-39

(5)

A

Dilazep

150

-21.8

Sigma

A

Dipyridamole

51.6

-24.5

Sigma

A

formycin A

36.5

-25.3

(8)

A

Hypoxanthine

500

-18.8

Sigma
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Supplemental Table 1 (continued)
Ki of P2 (µM)

(G0)
(kJ/mol)

Source

A

9

-28.8

(1)

A

19.9

-26.8

(1)

Scaffold

Compound
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Supplemental Table 1 (continued)
Scaffold

Compound

A

Ki of P2 (µM)

(G0)
(kJ/mol)

Source

74.5

-23.6

Sigma

17.1

-27.2

Sigma

A

Nebularine (purine riboside)

A

Oxypurinol

303

-20.1

Sigma

A

Purine

18.1

-27.1

Sigma
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Supplemental Table 1 (continued)
Ki of P2 (µM)

(G0)
(kJ/mol)

Source

A

16.2

-27.3

(3)

A

9.7

-28.6

(3)

3.81

-30.9

Fluka

8.2

-29

(6)

Scaffold

A

Compound

Tubercidin (7-deazaadenosine)

A
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Supplemental Table 1 (continued)
Scaffold

Compound

A

Ki of P2 (µM)

(G0)
(kJ/mol)

Source

125

-22.3

(6)

A

Xanthine

106

-22.7

Sigma

B

2-hydroxybenzamidine

2030

-15.4

Acros

B

3-aminobenzamidine

722

-17.9

Acros

B

4-aminobenzamidine

22.9

-26.5

Acros

B

Benzamidine

111

-22.6

Sigma

B

furamidine

1.19

-33.8

(5)

B

DB103

31.4

-25.7

(5)
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Supplemental Table 1 (continued)
Scaffold

Compound

Ki of P2 (µM)

(G0)
(kJ/mol)

Source

B

DB1061

7.07

-29.4

(5)

B

DB1064

33.2

-25.6

(5)

B

DB1111

5.5

-30

(5)

B

DB1138

8.1

-29.1

(5)

B

DB1213

1.09

-34

(5)
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Supplemental Table 1 (continued)
Scaffold

Compound

Ki of P2 (µM)

(G0)
(kJ/mol)

Source

B

DB1339

25

-26.3

(5)

B

DB1680

0.95

-34.4

(5)

B

DB244

3.23

-31.3

(5)
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Supplemental Table 1 (continued)
Scaffold

Compound

Ki of P2 (µM)

(G0)
(kJ/mol)

Source

B

DB249

4.49

-30.5

(5)

B

DB320

0.39

-36.6

(5)

B

DB544

3.02

-31.5

(5)

B

DB60

13.8

-27.7

(5)
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Supplemental Table 1 (continued)
Scaffold

Compound

Ki of P2 (µM)

(G0) (kJ/mol)

Source

Scaffold

B

DB607

4.1

-30.8

(5)

B

DB629

0.88

-34.6

(5)

B

DB686

5.4

-30.1

(5)

B

DB820

1.95

-32.6

(5)

B

DB829

1.4

-33.4

(5)
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Supplemental Table 1 (continued)
Scaffold

Compound

Ki of P2 (µM)

(G0) (kJ/mol)

Source

Scaffold

B

DB867

4

-30.8

(5)

B

DB931

1.23

-33.7

(5)

B

Distamycin A

10.6

-28.4

Sigma

B

1.36

-33.5

(9)

B

0.92

-34.5

(9)
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Supplemental Table 1 (continued)
Ki of P2 (µM)

(G0)
(kJ/mol)

Source

B

3.92

-30.9

(9)

C

8.05

-29.1

(12)

C

0.38

-36.6

(12)

C

0.81

-34.8

(12)

Scaffold

Compound
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Supplemental Table 1 (continued)
Ki of P2 (µM)

(G0)
(kJ/mol)

Source

C

0.21

-38.1

(12)

C

1.01

-34.2

(12)

C

1.57

-33.1

(12)

C

11.9

-28.1

(13)

Scaffold

Compound
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Supplemental Table 1 (continued)
Ki of P2 (µM)

(G0)
(kJ/mol)

Source

C

59.3

-24.1

(13)

C

5.8

-29.9

(10)

Scaffold

Compound

C

2-aminopyridine

14.3

-27.7

Aldrich

C

4,6-diaminopyrimidine

3.22

-31.3

Aldrich

C

4-aminopyridine

145

-21.9

Aldrich

C

4-aminopyrimidine

137

-22.1

Acros

C

4-hydroxybenzamidine

235

-20.7

Aldrich

C

butamidine

1.04

-34.2

(2)

-32.1

SanofiAventis

C

stilbamidine

2.42
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Supplemental Table 1 (continued)
Ki of P2 (µM)

(G0)
(kJ/mol)

Source

D

0.33

-37

(14)

D

129

-22.2

(14)

D

53.4

-24.4

(14)

D

4.6

-30.5

(14)

Scaffold

Compound
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Supplemental Table 1 (continued)
Ki of P2 (µM)

(G0)
(kJ/mol)

Source

D

404

-19.4

(14)

D

13.1

-27.9

(14)

D

3.65

-31

(14)

D

1.58

-33.1

(14)

Scaffold

Compound
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Supplemental Table 1 (continued)
Scaffold

Compound

D

Ki of P2 (µM)

(G0)
(kJ/mol)

Source

2.88

-31.6

(14)

D

Heptamidine

0.28

-37.4

(2)

D

Hexamidine

0.43

-36.3

(2)

D

iodo-pentamidine

0.27

-37.5

(4)

D

Megazol

192

-21.2

(15)

D

Octamidine

0.48

-36.1

(2)

D

Pentamidine

0.37

-36.7

Sigma

D

Propamidine

1.92

-32.6

(11)

E

1,1'-(nonane-1,9-diyl)diguanidine

45.4

-24.8

Biomol

200

-21.1

(9)

E
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Supplemental Table 1 (continued)
Ki of P2 (µM)

(G0)
(kJ/mol)

Source

E

3.25

-31.3

(9)

E

8.75

-28.9

(9)

F

9.3

-28.7

(12)

F

0.38

-36.6

(13)

F

0.38

-36.6

(12)

Scaffold

Compound
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Supplemental Table 1 (continued)
Scaffold

Compound

F

Ki of P2 (µM)

(G0)
(kJ/mol)

Source

37.7

-25.3

(3)

SanofiAventis
SanofiAventis

F

melarsen oxide

9.7

-28.6

F

Melarsoprol

0.54

-35.8

F

Thiamine

364

-19.6

Sigma

G

Aminopterin

78.4

-23.4

Sigma

G

diminazene aceturate (berenil)

2.36

-32.1

Sigma

G

Ethidium

5.96

-29.8

Sigma

G

Isometamidium

0.21

-38.1

May &
Baker

(1) Gift of Professor Gerrit-Jan Koomen, University of Amsterdam; Amsterdam, The Netherlands.
(2) Gift of Professor Alan Fairlamb, University of Dundee; Dundee, UK.
(3) Gift of Professor Katherine Radtke-Seley, University of Maryland, Baltimore Co; Baltimore, MA, USA.
(4) Gift of Dr Philip Blower, University of Kent at Canterbury; Canterbury, UK.
(5) Gift of Professor David Boykin, Georgia State University; Atlanta, GE, USA.
(6) Gift of Professor Achiel Haemers, University of Antwerp; Antwerp, Belgium.
(7) Gift of Professor Mahmoud H. el Kouni, University of Alabama at Birmingham; Birmingham, AL, USA.
(8) Gift of Professor Simon Jarvis, University of Westminster; London, UK.
(9) Gift of Dr Paul O’Neil, University of Liverpool; Liverpool, UK.
(10) Gift of Professor Richard Tidwell, University of North Carolina, Chapel Hill; NC, USA.
(11) Gift from Dr Christophe Dardonville, Instituto de Química Médica; Madrid, Spain.
(12) Gift from Professor Ian Gilbert, University of Dundee, UK; see Stewart et al. (2005) Antimicrob. Ag. Chemother. 49, 5169-5171.
(13) Gift from Professor Ian Gilbert, University of Dundee, UK; see Tye et al (1998) Bioorg Med Chem Lett 8, 811-816 and Klenke et al. (2001) J. Med. Chem. 44, 3440-3352.
(14) Gift from Professor Ian Gilbert, University of Dundee, UK; see Stewart et al (2004) Antimicrob. Ag. Chemother. 48, 1733-1738 and Baliani et al (2005) J. Med. Chem. 48, 5570-5579.
(15) Gift from Professor Bernard Bouteille, Institut d’Epidémiologie Neurologique et de Neurologie Tropicale, Limoges, France.
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0

Supplemental Table 2. Listing of K values, Gibbs free energy ΔG and energy gain/loss relative to a control compound for some of the
i

compounds utilised in this study and listed in Supplemental Table 1. Conclusions drawn from the data with respect to substrate
binding of the P2 transporter are listed in the final column.
Compound

Ki value (μM)

Δ(G0)
(KJ/mol)

Adenosine

0.92 ± 0.06

34.5

δ(Δ(G0))
(KJ/mol)

Relative to

Conclusion

N/A

Average contribution of 7.7 kJ/mol to
binding the purine ring.

Position 1
1-Deazaadenosine

45.4 ± 8.7

24.8

9.7

Adenosine

N1 contributes of 9.7 kJ/mol to binding
of adenosine.

1-Deazapurine

181 ± 33

21.4

5.7

Purine

N1 contributes of 5.7 kJ/mol to binding
of adenine.
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Supplemental Table 2 (continued)
Compound

Ki value (μM)

Δ(G0)
(KJ/mol)

δ(Δ(G0))
(KJ/mol)

Relative to

Depending on the group, substitutions
on position reduce binding energy of
adenosine analogs with 5 – 11 kJ/mol.

Position 2
2-Nitroadenosine

81 ± 22

23.4

11.1

Adenosine

2-Hydroxy-6-aminopurine

9.7 ± 2.3

28.6

8.7

Adenine

2,6-Diamino, 2’deoxypurine
riboside

4.4 ± 1.3

30.5

7.4

2’-Deoxyadenosine

2-Chloroadenosine

9.7 ± 3.4

28.6

5.9

Adenosine

N3 does not contribute to binding. Its
removal re-distributes charge around
the molecule, resulting in a slightly
higher affinity.

Position 3

3-deazaadenosine

Conclusion

0.29 ± 0.06

37.3

-2.8

Adenosine
The 6-NH2 group contributes an
average of 8.2 kJ/mol to binding of
aminopurines.

Position 6
6-chloropurine riboside

15.4 ± 0.8

27.5

7.0

Adenosine

Purine

18.1 ± 3.2

27.1

10.2

Adenine

Purine riboside

17.1 ± 2.1

27.2

7.3

Adenosine
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Supplemental Table 2 (continued)
Compound

Ki value (μM)

Δ(G0)
(KJ/mol)

δ(Δ(G0))
(KJ/mol)

Relative to

Conclusion
The binding energies of positions 1 and
6 are additive, resulting in very low
affinity for inosine and guanosine, and
is estimated at 15.7 kJ/mol.

Positions 6 and 1

Guanosine

>500

Inosine

>500

2’-deoxyinosine

165 ± 23

21.6

16.3

2’-Deoxyadenosine

1-deazapurine

131 ± 34

22.2

15.1

Adenine

Loss of affinity can be attributed solely
to the substitution on position 2 (see
above). The single substitution at the 6amine position is therefore not (greatly)
detrimental to binding, especially when
the substitution is small or flexible.

Positions 6 and 2

21 ± 9.2

8.6

Adenosine
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Supplemental Table 2 (continued)
Compound

Ki value (μM)

Δ(G0)
(KJ/mol)

9.0 ± 1.7

δ(Δ(G0))
(KJ/mol)

Relative to

5.7

Adenosine

Conclusion

Small apparent contribution to binding
from N7, though too small to represent
a full hydrogen bond. The absence of
N7, however, decreases the positive
charge on N9.

Position 7

7-deazaadenosine (tubercidin)

3.8 ± 0.7

30.9

3.6

Adenosine

Formycin A

36.5 ± 6.6

25.3

9.2

Adenosine
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Supplemental Table 2 (continued)
Compound

Ki value (μM)

Δ(G0)
(KJ/mol)

δ(Δ(G0))
(KJ/mol)

Relative to

Substitutions at position 8 are
detrimental to binding.

Position 8
8-azidoadenosine

331 ± 142

19.9

14.6

Adenosine

8-bromoadenosine

37.8 ± 8.2

25.2

9.2

Adenosine

Significant contribution of N9 to
adenosine binding.

Position 9
9-deazaadenosine

Conclusion

12.1 ± 3.2

28.1

6.4

Adenosine

Absence of the ribose or of just the 2’hydroxyl group increases affinity by
approximately 3 kJ/mol.

Ribose
Adenine

0.30 ± 0.02

37.3

-2.8

Adenosine

2’-deoxyadenosine

0.23 ± 0.04

37.9

-3.4

Adenosine
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Supplemental Table 2 (continued)
Compound

Ki value (μM)

Δ(G0)
(KJ/mol)

δ(Δ(G0))
(KJ/mol)

Relative to

Conclusion

The aromaticity of the purines and
diamidines contributes importantly to
their high affinity binding of P2, as nonaromatic diamidines or diguanidines of
similar length and flexibility as the
aromatic diamidines display ~100-fold
less affinity, corresponding to 10-11
kJ/mol in binding energy. Presumably
π−π-bonds with aromatic amino acid
residues are involved in substratetransporter interactions.

Aromaticity

>200

45 ± 15

24.7

Pentamidine

0.37 ± 0.04

36.7

Propamidine

1.9 ± 0.8

32.6

Stilbamidine

2.4 ± 0.3

32.0

11.9
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Pentamidine

Dataset E

Dataset G
Dataset F

Supplemental Figure 1. Initial alignments for datasets E, F and G.
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Appendix B

Supplemental Table 3. Training dataset of compounds with experimentally determined inhibition (IC50) values against L. donovani
(LD) and L. amazonensis (LA).
Name

Structure

LD

LA

DB667

1.6 ± 0.4

0.53 ± 0.19

DB702

0.67 ± 0.14

0.29 ± 0.13

DB709

0.53 ± 0.19

0.37 ± 0.15

DB745

0.50 ± 0.15

0.12 ± 0.02
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Supplemental Table 3 (continued)
Name

Structure

LD

LA

DB750

1.50 ± 0.13

0.96 ± 0.33

DB766

0.50 ± 0.10

0.087 ± .015

DB780

4.5 ± 0.9

0.51 ± 0.09

DB894

1.2 ± 0.1

0.62 ± 0.20
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Supplemental Table 3 (continued)
Name

Structure

LD

LA

DB946

0.37 ± 0.04

0.11 ± 0.03

DB1831

0.55 ± 0.17

0.70 ± 0.16

DB1848

31 ± 7

5.0 ± 1.5

DB1850

1.4 ± 0.4

0.17 ± 0.06
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Supplemental Table 3 (continued)
Name

Structure

LD

LA

DB1851

>50

>10

DB1852

1.4 ± 0.2

0.17 ± 0.06

DB1853

1.5 ± 0.3

0.21 ± 0.07

DB1855

20 ± 6

3.7 ± 3.2
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Supplemental Table 3 (continued)
Name

Structure

LD

LA

DB1858

16 ± 4

0.90 ± 0.07

DB1859

>100

>10

DB1860

>100

>10

DB1861

>100

>10

DB1862

1.1 ± 0.4

0.25 ± 0.04
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Supplemental Table 3 (continued)
Name

Structure

LD

LA

DB1863

2.5 ± 0.2

0.59 ± 0.08

DB1867

0.68 ± 1.8

0.045 ± 0.011

DB1868

1.0 ± 0.1

0.13 ± 0.07
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Supplemental Table 3 (continued)
Name

Structure

LD

LA

DB1875

28 ± 4

>10

DB1876

28 ± 4

2.1 ± 0.9

DB1880

59 ± 9

> 10
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Supplemental Table 3 (continued)
Name

Structure

LD

LA

DB1888

>100

>10

DB1889

>100

>10

DB1890

1.1 ± 0.2

0.095 ± 0.018

199

Supplemental Table 3 (continued)
Name

Structure

LD

LA

DB1906

1.9 ± 0.5

0.27 ± 0.04

DB1907

4.5 ± 0.2

2.7 ± 0.7

DB1909

23 ± 4

>10
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Supplemental Table 3 (continued)
Name

Structure

LD

LA

DB1913

>50

>10

DB1920

2.4 ± 0.6

0.49 ± 0.08

DB1921

41 ± 3

4.7 ± 0.7
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Supplemental Table 3 (continued)
Name

Structure

LD

LA

DB1937

1.1 ± 0.2

1.1 ± 0.1

DB1938

21 ± 2

1.7 ± 0.4

DB1939

>100

0.22 ± 0.02
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Supplemental Table 3 (continued)
Name

Structure

LD

LA

DB1940

0.82 ± 0.10

0.64 ± 0.19

DB1942

3.6 ± 1.1

0.81 ± 0.20

DB1943

1.3 ± 0.3

0.30 ± 0.10
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Supplemental Table 3 (continued)
Name

Structure

LD

LA

DB1950

5.1 ± 1.2

>10

DB1951

28 ± 2

>10

DB1952

7.9 ± 1.5

0.32 ± 0.07
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Appendix C

Supplemental Table 4. Compounds with experimentally determined inhibition (IC50) values against Trypanosoma cruzi.
No.

ID

1

Compound

4°C

37°C

1MAA119

32

2.3

2

6SMB038

400

19

3

9SMB070

229.3

20.9

4

10SAB031

32

32

5

10SAB055

91.6

32

6

10SAB092

32

32

7

11SAB003

400

2.7
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Supplemental Table 4 (continued)
No.

ID

8

Compound

4°C

37°C

12SMB032

32

32

9

14SMB013

32

9.3

10

16SAB065

400

32

11

18SMB092

32

32

12

18SMB096

32

32

13

21DAP023

128.6

0.7

14

21DAP027

400

32

15

24SMB001

128.6

1
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Supplemental Table 4 (continued)
No.

ID

16

Compound

4°C

37°C

25DAP009

400

1.9

17

25DAP013

32

6.1

18

27DAP060

135.8

16.3

19

27DAP080

400

32

20

150OXD049

32

32

21

DB613A

1.96

4.05

22

DB702

1.18

0.45
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Supplemental Table 4 (continued)
No.

ID

23

Compound

4°C

37°C

DB711

32

19.4

24

DB766

0.11

0.06

25

DB786

32

0.015

26

DB824

15.54

4.43

27

DB889

0.97

0.09

28

DB1080

1.77

0.24

29

DB1195

1.21

0.26
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Supplemental Table 4 (continued)
No.

ID

30

Compound

4°C

37°C

DB1196

0.81

1.19

31

DB1201

6.6

1.77

32

DB1345

3.72

0.91

33

DB1362

7

6.6

34

DB1582

32

6

35

DB1627

32

32

36

DB1645

32

0.15

37

DB1646

32

31

38

DB1651

32

6.9
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Supplemental Table 4 (continued)
No.

ID

39

Compound

4°C

37°C

DB1670

32

32

40

DB1831

0.08

0.02

41

DB1850

2.35

0.19

42

DB1852

32

0.06

43

DB1853

0.14

0.07

44

DB1862

0.79

0.06
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Supplemental Table 4 (continued)
No.

ID

45

Compound

4°C

37°C

DB1867

0.7

0.02

46

DB1868

0.28

0.06

47

DB1890

32

0.01
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